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and! the!growth!plate!of! growing!bones.! ! In!particular,! the! inflammation! causes!a!
functional! insensitivity! to! GH,! resulting! in! low! circulating! IGF\1.! ! Current!
management! is! synonymous! with! the! optimal! management! of! childhood! CD:! to!
eliminate! inflammation,! and!maintain! remission.! ! However,! there! is! currently! no!
consensus! as! to! how! to! treat! growth! failure! in! patients! whose! inflammation!
remains!intractable!to!treatment.!
This! thesis! examined! the! hypothesis! that! successful! treatment! of! inflammation!
would! improve! linear! growth! in! children! with! CD.! ! We! performed! a! series! of!
retrospective!studies!examining!a!cohort!of!children!aged!≤17!years!with!CD!treated!
at! Bart’s! and! The! London! Children! Hospital.!We! determined! the! height! standard!
deviation! scores! (SDS)!of!patients! at!diagnosis! and! investigated!growth!outcomes!
following!treatments!used!to!induce!and!maintain!remission.!These!were:!exclusive!
enteral! nutrition! (EEN),! thiopurines! and! infliximab.! Finally,! as! a! potential! new!
therapy,!we!considered!the!use!of!exogenously!administered!recombinant!human!
IGF\1! (rhIGF\1)! to! restore! plasma! IGF\1! levels.! ! We! performed! an! open\labelled!
pharmacokinetic!(PK)!study!of!rhIGF\1!in!8!children!with!CD!and!growth!failure.!
9%! of! our! patients! had! height! SDS! of! \2! SDS! at! diagnosis;! a! four\fold! increase!
compared! to! the!normal! age!matched!population.! In! addition,! symptom!duration!









with! thiopurines! were! in! remission! at! 12!months.! ! These! patients! had! improved!
growth!(median!change!height!SDS![IQR]!0.08![\0.06!–!0.19]!vs!\0.24![\0.61!\!\0.07]!





of! IGF\1! in! our! patients,! albeit! it! in! some! to! high! levels! (median! [range]!
concentration!+2.09![\1.27!to!+5.21]).!We!were!able!to!develop!a!PK!mathematical!
model!from!these!results!to!determine!a!more!appropriate!dosage.!!We!found!that!




a! number! of! children! continued! to! have! poor! growth! despite! treatment.! ! Our!






















































































































































































































































































































































































































































Rao! A,! Standing! JF,! Naik! S,! Savage!MO,! Sanderson! IR.!Mathematical!modeling! to!
restore! circulating! IGF\1! concentrations! in! children! with! Crohn's! disease\induced!
growth!failure:!a!pharmacokinetic!study.!BMJ!Open.!2013!May!28;3(5).!
Goodhand!JR,!Tshuma!N,!Rao!A,!Kotta!S,!Wahed!M,!Croft!NM,!Sanderson!IR,!Epstein!
J! &! Rampton! DS.! Do! children! with! IBD! really! respond! better! than! adults! to!





Rao!A,! Tshuma!NB,!Goodhand! JR,!Wahed!M,! Croft!NM,! Epstein! J,! Sanderson! IR! .!
Response!to!azathioprine!in!adults!and!children!with!inflammatory!bowel!disease!is!
comparable!when!phenotype! is! controlled.! Journal!of!Pediatr!Gastroenterol!Nutr.!
2010;50(Suppl.!2):E112.!
!












Rao! A,! Kamperidis! N,! Koodun! Y,! Naik! S,! Croft! NM,! Sanderson! IR! .! Response! to!



























Crohn's! disease! (CD)! is! a! form! of! inflammatory! bowel! disease! (IBD);! a! group! of!
chronic,! idiopathic! inflammatory! disorders! of! the! bowel! which! also! include!
ulcerative!colitis!(UC),!indeterminate!colitis,!and!rare!(mostly!genetic)!conditions!of!
early!infancy![1].!!CD!can!occur!in!both!adults!and!children,!and!can!involve!any!part!
of! the! gastrointestinal! tract! from! the! oropharynx! to! the! perianal! area! with!
discontinuous! inflammation! ('skip! lesions').! ! It! is! characterised! by! transmural!
inflammation!of!the!bowel!wall.!!As!a!result,!there!is!a!tendency!to!form!strictures!
and!fistulae.!!The!inflammation!of!CD!is!histologically!identified!as!cryptitis!with!the!
formation!of! crypt! abscesses! and,! in!many!patients,! granulomas.! ! CD! is! a! chronic!
lifelong! condition.! ! It! runs! a! relapsing! and! remitting! course.! ! There! are! several!












is! triggered! by,! as! yet! mostly! undefined,! environmental! insults! that! transiently!
break! the! mucosal! barrier,! stimulate! immune! responses! or! alter! the! balance!
between! enteric! bacteria! [3,! 4].! ! Enteric! microbiota! can! stimulate! immune!
responses,! either! by! functioning! as! adjuvants! or! antigens.! ! As! adjuvants! they!
activate! innate! immune! responses! (including! dendritic! cells! and! other! antigen!
presenting!cells)!and!as!antigens!they!stimulate!the!clonal!expansion!of!T\cells!that!
selectively!recognise!the!antigen!through!their!T\cell!receptor.!!Therefore,!patients!
with! CD! have! enhanced! recruitment! and! retention! of! effector! macrophages,!




population! risk,! and! where! both! parents! have! CD! up! to! 36%! of! offspring! will!
develop! the! disease! [5\7].! ! Disease! location! is! also! highly! concordant! between!
monozygotic!twins!with!Crohn’s!disease.!!A!Scandinavian!study!found!that!location!
was!identical! in!11!out!of!17!monozygotic!twins!with!Crohn’s!disease!at!diagnosis,!
and! behaviour! in! 13/17! pairs! [8].! ! This! similarity! was! still! seen! after! 10! years! of!
disease.!!By!contrast,!monozygotic!twins!with!UC!were!concordant!for!age!of!onset,!
but!not!for!extent!of!disease!at!diagnosis!or!after!10!years.!
The! first! IBD! genetic! susceptibility! gene! to! be! discovered! was! CARD\15! (caspase!
recruitment!domain!family!member\15).!!This!encodes!for!an!intracellular!receptor!





pivotal! relationship!between! the!gut! immune! system!and! intestinal!microbiota!at!
the!heart!of!CD!pathogenesis.! !Since! then,!several!other!susceptibility!genes!have!
been! identified,! including!solute!carrier! family!22!members!4!and!5!(SLC22A4!and!
SLC22A5!(organic!cation!transporter)![11,!12]!and!discs!large!homolog!5!(DLG5;!an!
epithelial! scaffolding! protein)! [13].! ! The! commonality! between! these! implicated!
genes! is! that! they! all! regulate! several! important! biologic! functions,! including!
mucosal! barrier! integrity,! immunoregulation! and! microbial! clearance! and! /! or!
homeostasis![3].!
The! involvement!of! the! intestinal!microbiota! in! the!pathogenesis! of! CD!has! been!
well! described.! ! Animal! models! have! demonstrated! that! colitis! and! immune!
activation!fail!to!develop!in!the!absence!of!commensal!bacteria![14].!!Furthermore,!
patients!with!CD!exhibit!altered!intestinal!microbiota,!including!reduced!Firmicutes!
such! as! Clostridia! cluster! IV! and! Faecalibacterium, prausnitzii, and! increased!
Escherichia,coli,[4,!15,!16].!!However,!sibling!studies!have!shown!that!asymptomatic!
siblings! of! patients! with! CD! share! aspects! of! their! intestinal! dysbiosis! without!
developing! the! disease! itself! [17].! ! The! relatively! low! concordance! of! CD! in! twin!
studies! [8]!and! the! increased!prevalence!of!CD! in!countries!as! they!adapt!a!more!
'Western'! lifestyle![18]! indicates!that!there! is!a!strong!environmental! influence!on!
IBD.!!Studies!have!implicated!several!environmental!factors!in!the!pathogenesis!of!
CD,! including! smoking,! stress,! infections,! diet! and! the!use!of! antibiotics! and! anti\
inflammatory!drugs![3,!19\23].!!!






all! resulting! in! similar! final! common!pathways.! ! This! theory! could!predict!why!no!






































































































































































































































































































































































































































































































































































































































































































































































course! [26,! 27].! ! In! addition,! childhood! is! a! time! of! significant! physical! changes! and!
emotional!maturation.!!There!is!also!the!likelihood!of!many!years!of!treatment,!and!so!









Eastern! Europe! [29,! 30].! ! This! increase! is! likely! to! be! related! to! westernization! of!
lifestyle,!altered!diet!and!changes!in!hygiene![31].!
The! incidence!of!paediatric!CD! is!also! increasing![24,!32934].! ! !A!systemic!review!was!
performed!describing!the!changing!epidemiology!of!childhood!onset!IBD![24]!.!!Articles!
published! between! 195092009!were! searched! and! analysed.! ! Of! the! 25! studies! that!









that! the! prevalence! of! paediatric! CD!has! increased! from!23.9/100,000! population! in!
1994! to! 31.6/100! 000! in! 2005! [32].! ! By! contrast,! Malmborg! et! al! [36]! found! that!
although! the! incidence! rate! of! paediatric! IBD! (PIBD)! in! northern! Stockholm! was!
significantly! higher! in! 200292007! than! 199092001,! the! previous! sharp! increase! in! CD!




onset! of! CD! was! 12.3! years,! with! the! highest! age9related! incidence! occurring! at! 14!
years! [37].! ! There! is! conflicting! data! as! to! whether! the! median! age! of! onset! of!




aged! 599! years! old! (8.7%! per! year,! p<0.0001)! [32].! ! However,! retrospective! data!
analysed! from! patients! enrolled! in! the! Swiss! IBD! Cohort! Study! showed! that! age! of!
onset! had! increased! between! 198092010! [38].! In! addition,! a! retrospective! study! of!
children! diagnosed! with! IBD! between! 199192002! in! Texas! showed! a! significantly!




incidence! in! children!under!10.! ! The!highest! incidence!was! in! children!ages!10914yrs!
was!among!both!patients!with!CD!and!those!with!UC![39].!!!!
In!contrast!to!adults,!in!whom!females!are!more!commonly!affected!than!males!both!
in! adult9onset! and! elderly9onset! CD,! there! is! a! male! predilection! in! the! paediatric!
population![40].!!The!male:!female!ratio!is!commonly!described!as!being!around!1.5:1!





The! classic! triad! of! presenting! symptoms! is! that! of! pain,!weight! loss! and! diarrhoea.!
However,!a!large!population9based!survey!in!the!United!Kingdom!found!that!only!25%!
of! patients! presented! with! all! three! symptoms.! ! A! substantial! minority! of! patients!
(44%)!did!not!have!diarrhoea.! ! The! commonest!presenting! symptom!was! abdominal!
pain,!with!72%!of!patients!reporting!this.!!Other!presenting!features!included!fatigue,!





CD,!as!with!all! the!other! inflammatory!bowel!diseases,! is! also!associated!with!extra9














The! importance! of! having! uniformity! in! the! investigations! and! criteria! used! for!
diagnosis!of!paediatric! IBD!has!been!recognised.! ! In!2005,! the! IBD!Working!Group!of!
the! European! Society! of! Pediatric! Gastroenterology! Hepatology! and! Nutrition!
(ESPGHAN)! published! the! Porto! criteria! for! diagnosis! [46].! ! These! criteria! have! been!
revised! recently! (Figure! 1.2).! ! They! state! that! accurate! diagnosis! of! IBD! should! be!
based! on! a! combination! of! history,! physical! and! laboratory! examination,!
esophagogastroduodenoscopy!and!ileocolonoscopy!with!histology,!and!imaging!of!the!

























Figure! 1.2! Evaluation! of! child/adolescent! with! intestinal! or! extraintestnal! symptoms!
suggestive!of!IBD.!!
Atypical!UC!is!a!new!IBD!category!and!reflects!a!phenotype!that!should!be!treated!as!UC.!IBD9U!
can! be! used! as! a! tentative! diagnosis! after! endocscopy,! and! can! be! used! as! a! final! diagnosis!
after!imaging!and!a!full!endoscopic!workup.!UC!is!divided!into!typical!UC!and!atypical!UC,!CD!=!




























The! various! phenotypes! of! CD! in! adults! and! children! are! defined! by! the! Montreal!






Age!of!onset Location! Behaviour!** 
<16!years!(A1) Ileal!(L1) Non9stricturing,!non9
penetrating!(B1) 
16940!years!(A2) Colonic!(L2) Stricturng!(B2) 
>40!years!(A3) Ileo9colonic!(L3) Penetrating!(B3) 







[26].! ! Studies! show! that! as! many! as! 63%! of! children! have! ileocolonic! disease! at!
diagnosis,!whereas!in!adults!the!most!common!site!of!disease!at!presentation!is!ileal.!!
When!followed!up!over!a!period!of!at!least!2!years,!approximately!one!third!of!patients!
















Therefore,! the! Paris! classification! has! since! been! proposed.! ! This! has! now! further!




growth! failure! is! also!noted,!with!G1! indicating! growth! impairment! in! the!patient! at!


















































Growth! n/a! G0:!No!evidence!of!growth!delay! 
G1:!Growth!delay 
*In!both!the!Montreal!and!Paris!Classification!systems!L4!and!L4a/L4b!may!coexist!with!L1,!L2,!
L3,! respectively.!B1! –! Non9stricturing,! non9penetrating! disease:! uncomplicated! inflammatory!
disease!without!evidence!of!stricturing!or!penetrating!disease.!
B2! 9! Stricturing! disease:! the! occurrence! of! constant! luminal! narrowing! demonstrated! by!
radiologic,! endoscopic,! or! surgical! examination! combined! with! prestenotic! dilation! and/or!
obstructive!signs!or!symptoms!but!without!evidence!of!penetrating!disease.!
B3! 9! Penetrating! disease:! the! occurrence! of! bowel! perforation,! intraabdo9! minal! fistulas,!
inflammatory! masses! and/or! abscesses! at! any! time! in! the! course! of! the! disease,! and! not!





























Most! healthy! children! grow! in! a! predictable! fashion,! following! a! typical! pattern! of!






Normal! linear! growth! in! children! occurs! via! activation! of! the! growth! hormone! (GH)!
insulin9like!growth!factor91!(IGF91)!axis!while!supported!by!adequate!nutrition.! !GH!is!






complexes! with! high9affinity! binding! proteins! (IGFBPs)! and! the! acid9labile! subunit!
(ALS).!!IGF91!first!binds!to!an!IGFBP,!followed!by!the!binding!of!ALS![63].!!The!formation!
of! this! ternary! complex! restricts! IGF91! to! the! circulation,! prolonging! its! half9life,! and!
modulating!its!bioavailability![64].!.!!There!are!currently!6!known!IGFBPs.!!Most!serum!
IGF91!binds!to! IGFBP93,!and! !GH! in!turn!regulates!this! [54,!64].! !Of! the!other!binding!
proteins,! IGFBP91! is! regulated! primarily! by! insulin! levels,! but! expression! is! also!
increased! in! states! of! starvation! and! by! corticosteroids! (CS)! in! a! dose9dependent!
manner.!!Factors!that!increase!IGFBP91!may!decrease!the!availability!of!bioactive!IGF91!
[54].!!!







as! chronic! renal! disease! [68970],! Turner's! Syndrome! [71]! and! Prader9Willi! syndrome!
[72].! !Treatment!with! recombinant!human!GH!(rhGH)! replacement! therapy!has!been!
shown!to!improve!growth!in!these!patients![73979].!!!
The!importance!of!IGF91!has!similarly!been!demonstrated.!!IGF91!is!the!main!mediator!
of! GH! action! [80,! 81].! ! First! described! by! Laron! in! 1966! [82],! growth! hormone!
insensitivity! syndrome! (GHIS)! encompasses! a! variety! of! genetic! and! acquired!
conditions!in!which!the!action!of!GH!is!absent!or!reduced.!!Affected!children!have!very!
low! circulating! IGF91,! with! normal! or! elevated! GH,! resulting! in! severe! growth!
retardation.!Untreated!GHIS! results! in!adult!heights!4! to!12!standard!deviations! (SD)!
below! the! normal! [83985].! In! addition,! these! children! also! have! very! low! levels! of!























































score! <92)! [53,! 89].! !Where! possible,! it! is! of! benefit! to! calculate! the! patient’s! target!
height,!as!derived!from!parental!height.!!First!described!by!Tanner!in!1970!as!a!means!
of! testing! the! effectiveness! of! growth! promoting! therapies,! the! target! height! is!
commonly! determined! by! the! corrected! mid9parental! height! (adding! or! subtracting!
6.5cm! for! boys! and! girls,! respectively)! [90].! ! This! is! an! important! measurement! as!
family!and!twin!studies! in!the!general!population!have!shown!that!the!heritability!of!
growth! is!high,! ranging! from!76990%![91993].! !The!same!has!been!shown! in! IBD.! !An!
American! study! looking! at! the! impact! of! parental! height! to! final! adult! height! in! 108!
children!with!paediatric9onset! IBD! found! that! the!adult!heights!of! these!patients! fell!
within!1! SD!of! their! target!heights! [94].! !However,! this! study! included!both! children!
with!CD!and!UC!in!its!analysis.!!It!has!been!well!documented!that!children!with!UC!have!
less!growth!impairment!than!children!with!CD.!Therefore!the!inclusion!of!UC!patients!
is! likely! to! have! had! an! impact! upon! the! study! findings.! ! Nevertheless,! it! has!













between!1988! and! 2004,! 9.5%! showed!height! SDS! <! 92! at! diagnosis,!with! an! overall!
mean! score! of! 90.38! SD! [96].! ! In! some! patients,! growth! failure!may! precede! clinical!
evidence!of!bowel!disease!by!a!few!years![97].! !Kanof!et$al! (1988)!noted!that!88%!of!
patients!had!reduced!height!velocity!prior!to!diagnosis,!almost!half!of!whom!displayed!






such! as! abdominal! pain! and!weight! loss,!whereas! children!with! colitis! often! present!
with! bloody! diarrhoea! [100].! ! A! study! by! Sawczenko! et$ al! looking! at! the! presenting!




than! 3! years.! ! This! is! of! fundamental! importance! as! a! delay! in! time! to! diagnosis!
correlates!negatively!with!the!degree!of!growth!retardation![42,!101],!which!is!in!turn!




importance! of! prompt! recognition! and! treatment! of! children! with! CD! in! order! to!
improve!their!long9term!growth!outcomes.!
Another! factor! that!has!been! reported! to! correlate!with!growth! failure! is! the! site!of!
disease!location![99,!100].! !Sawczenko!et$al! found!that!the!presence!of!active!jejunal!
disease!was!associated!with!both!reduced!height!and!weight!z!scores!when!compared!
to!patients!with!other!disease! locations! (height!mean!z! score! 90.90!vs! 90.5;!p=0.041,!
weight!mean!z! score! 91.6!vs! 91.1;!p=0.02!respectively).! [42].! !Growth!retardation!can!
have!a!lasting!effect.!!A!study!at!Barts!Health!NHS!Trust,!examining!final!adult!height!in!
123! patients! diagnosed! with! CD! in! childhood,! found! that! the! presence! of! jejunal!
disease!was!not!only!associated!with!low!height!SDS!scores!at!diagnosis,!but!that!this!
persisted!into!adulthood.!!At!final!height,!the!patients!with!jejunal!disease!at!diagnosis!
were! shorter! than! those! without! jejunal! disease! (mean! height! SDS! 90.70! vs! 90.15;!
p=0.034)![101].!
The!data!as!to!whether!gender!has!an!impact!upon!the!amount!of!growth!impairment!
present! at! diagnosis! is! conflicting.!Generally,! it! is! described! as! being! greater! in! boys!




















































the! calorie! intake! in! 24! children!with! active! CD!was! on! average! 400! kcal/day! lower!
than!that!in!healthy!controls.!!Nutritional!supplementation!has!been!shown!to!improve!
growth! velocity! [110].! ! Aiges! et$ al! found! that! supplementing! growth! impaired! CD!
patients!with!overnight!nasogastric!(NG)!feeds!significantly!improved!both!their!weight!
and!height!over!a!12!month!period.!!The!mean!weight!gain!of!this!cohort!was!11.75kg,!
and!height! gain!was!6.98cm.! !As! a! comparison,!6! control! subjects,!matched! for! age,!
pubertal! status! and!degree!of! growth! retardation!who! refused!NG! feeds! showed!no!
change! in!weight!or!height!over!this!period![107].! !Other!factors!which!contribute!to!
the!malnutrition!are!malabsorption!and! increased!nutrient! loss! [54].! !Although! it!has!
been!postulated!that!children!with!active!CD!may!have!increased!energy!requirements,!
this! has! so! far! not! been!demonstrated! [111,! 112].! ! However,! children!with! CD!have!
been!shown!to!have!decreased!lean!body!mass!similar!to!that!seen!in!cachexia![113].!!
This! combination! of! protein! and! calorie!malnutrition! results! in! decreased! circulating!
levels! of! IGF91! and! IGFBPs! [114,! 115].! !Grinspoon!et$ al$ (1995)! found! that! circulating!
IGF91!levels!decreased!by!approximately!50%!after!only!4!days!of!fasting!in!otherwise!
healthy!adult!women![116].!!Starvation!results!in!an!acquired!GH!resistance.!!In!animal!











α! (TNF9α),! have! been! shown! to! interact! directly! at! appetite! centres,! causing! an!
anorexigenic!effect![119,!120].!!In!rats!with!experimentally!induced!colitis,!attenuating!
interleukin91! (IL91)! activity! by! intracerebroventricular! infusion! of! IL91! receptor! α!
significantly!improved!food!intake![119].!!Additionally,!in!patients!with!CD,!increases!in!
pro9inflammatory! cytokines! occur! in! association! with! alterations! in! hormones! that!
control!appetite,!such!as!polypeptide!YY![121]!and!ghrelin![122].!!!
Therefore,!it!is!very!difficult!to!separate!out!the!relative!contributions!of!inflammation!
and! undernutrition! upon! growth! failure.! ! However,! animal! studies,! in! which! it! is!
possible!to!control!calorie!intake,!have!assisted!with!this.!!Ballinger!et$al!(2000)!looked!
to!elucidate! the! relative!contributions!of! reduced!calorie! intake!and! inflammation! to!










values,! the! improvement! in!growth!did!not!match! that!of!control!values.! !These!rats!
remained!shorter!than!the!healthy!controls.!!By!contrast,!nutritional!supplementation!
caused! a! three9fold! increase! in! length! in! the! pair9fed! group!when! compared! to! the!
colitic!group!(p=0.007).!!From!this,!the!researchers!concluded!that!40%!of!the!growth!
retardation! in! the! TNBS! colitic! rats! occurred! as! a! direct! result! of! the! inflammatory!
process! independent! of! the! effects! of! undernutrition! (Figure! 1.4).! ! IL96! transgenic!
mouse!lines!bred!to!express!high!levels!of!circulating!IL96!from!early!after!birth!showed!
a! reduced!growth!rate! that!ultimately! led! to!mice!50970%!the!size!of!non9transgenic!
littermates.!!This!occurred!despite!comparable!food!intake!per!gram!of!body!weight!in!
both!groups.!!Moreover,!growth!was!improved!in!the!transgenic!mice!by!injecting!the!




















Linear! growth! retardation! in! rats!with! colitis! compared!with! healthy! free9feeding! controls!is!
due!to!both!undernutrition!and!inflammation!*p=0.02.!In!a!healthy!pair9fed!group,!food!intake!
is! restricted! to! that!of! the!colitic!group! resulting! in!equal!undernutrition,! thereby!separating!
the!effects!of! inflammation! from!nutritional! status.! The!difference! in! linear!growth!between!
the!pair9fed!rats!and!free9feeding!controls!is!the!contribution!of!undernutrition!**p=0.002;!the!
difference! between! the! colitic! group! and! the! pair9fed! group! is! the! contribution! of!
inflammation.!Values!are!mean!±!SD.!!Taken!from!Ballinger!et$al!Gut!2000![123]!
!
The! importance! of! IL96! to! growth! in! humans! has! also! been! demonstrated.! ! IL96!
expression!is!increased!in!CD,!and!circulating!levels!parallel!disease!activity![1269128].!!
In!humans,!the!IL69174!G/C!promoter!polymorphism!affects!IL96!transcription,!with!the!
GG! genotype! inducing! the! greatest! levels! over! GC! or! CC! genotypes! [129,! 130].!!



































Active! inflammation! is! associated!with! low! circulating! IGF91! levels.! ! Rats!with! TNBS9
induced!colitis!had!lower!circulating!IGF91!levels!than!their!healthy!counterparts![123].!!
The! same! has! been! demonstrated! in! children! not! only! with! CD,! but! also! in! other!
conditions!of! chronic! inflammation! [1319134].! ! Treatment!of! the! inflammation! in!CD!
results! in! an! increase! in! IGF91! levels! [133,! 135].! ! For! example,! treatment! with! an!
enteral! diet! causes! a! reduction! in! cytokines! such! as! IL96,! and! an! increase! in! IGF91!
within!3!days![136].!
Cytokines!have!several!points! in! the!GH/IGF91!pathway! that! they!can!act! (see!Figure!
1.5):! signal! transduction! of! GH! at! the! hepatocyte! level,! changes! in! IGFBP! levels,! or!
through! direct! effects! on! the! growth! plate.! ! Although! it! is! known! that! infusion! of! a!
cytokine! antibody! in! animal!models! enhance! growth,! it! is! difficult! to! know! at! what!




There! is! evidence! to! demonstrate! that! inflammation! causes! GH! insensitivity! at! the!
level!of!the!hepatocyte.!!Levels!of!GH!are!normal!in!children!with!CD!when!measured!
in! the!urine! [137],! including! after! stimulation! testing! [138].! ! Suppressor! of! cytokine9






in! deceased! IGF91! expression.! ! TNF9α! appears! to! lower! IGF91! by! down! regulating!
hepatic!expression!of!GH!receptor!in!mice!by!inhibiting!Sp1!and!Sp3!binding![139].!!!
As! previously! discussed,! IGF91! binds! to! IGFBPs,! which! modulate! its! bioavailability.!!
IGFBP93,! in! combination! with! acid! labile! subunit! (ALS),! increases! IGF91! availability.!!




In$ vitro! experiments! investigating! the! effect! of! cytokines! on! the! growth! plate! have!
produced! conflicting! results.! ! In! fetal! rat! metatarsal! growth! plates,! IL96! and! IL96!










































































































































































































































































































































































































































































































































































Puberty! is! the! period! of! time! during! which! adolescents! reach! sexual! maturity! and!














[149],! but! is! also! commonly! seen! in! girls.! ! An! American! study! by! Gupta! et# al! [150]!
compared!the!age!at!menarche!of!34!girls!with!CD!to!that!of!545!controls.!!They!found!
that!the!median!age!of!menarche!in!girls!with!CD!was!13.9!years,!as!compared!to!12.0!





The! aetiology! of! delayed! puberty! in! CD! is!multiSfactorial.! ! Undernutrition! is! a!major!
contributing! factor.! ! It! is! well! known! that! a! low! body! mass! index! (BMI)! results! in!
pubertal! delay! [151,! 152].! ! As! has! been!mentioned! previously,! children!with! CD! are!
often! underweight! for! their! age! and! gender! [42],!with! reduced! calorie! intake! [107].!!
However,! some! children!with! persistently! active! disease! do! not! enter! puberty! even!





inflammatory! cytokines! have! an! active! role! in! this! [89].! ! However,! as! it! is! still! not!








curative.! ! The! aim! of! management! in! all! patients! is! to! induce! remission! and! then!
maintain!the!remission!for!as!long!as!possible,!while!minimising!side!effects!as!a!result!
of! treatment! [155].! !As!has!been!discussed,!growth! failure! in!active!CD! is!associated!
with! malnutrition,! increased! proSinflammatory! cytokines! and! decreased! circulating!




Therefore,! the! first! principle! of! treatment! for! growth! restrictive! patients! is!
synonymous!with!the!optimal!management!of!childhood!CD![156].!!!!!!
It! is! now! felt! that! the! resolution! of! symptoms! alone! is! not! adequate! in! disease!






Exclusive! enteral! nutrition! (EEN)! refers! to! the! use! of! an! enteral! formula! (either!
elemental! or! polymeric),! which! is! given! exclusively! instead! of! a! normal! diet! for! a!
prescribed!period!of! time!to!patients!with!active!CD! in!order! to! induce!remission.! !A!
benefit!of!EEN!over!other!induction!agents!is!that!in!addition!to!its!proven!efficacy,!it!
has!an!excellent!safety!profile.! ! It!has!also!been!shown!to! improve!patient!quality!of!
life! [158].! ! Indeed,! the! recent!ECCO/ESPGHAN!guidelines!have! recommended!EEN!as!
the!induction!therapy!of!choice![55].!
!Nutritional!treatment!with!an!elemental!diet!was!initially!included!in!the!management!
of! CD! in! adults! to! provide! preSoperative! nutritional! support! [159].! ! However,! it!was!
noticed! that! these!patients! showed!an! improvement! in! their! symptoms! [160].! ! Total!
parenteral!nutrition!had!been!previously!used!as!form!of!therapy!on!the!basis!that! it!
provided! ‘bowel! rest’! [161].! !Following! these!observations,! several! clinical! trials! then!
proceeded!to!demonstrate!the!efficacy!of!EEN!as!a! treatment! for!active!CD! in!adults!





treatment,! 29! of! the! exacerbations! had! entered! remission! both! clinically! and!
biochemically.! !Following! from!this,! further!studies!have!demonstrated! its!efficacy! in!
children! [164],! and! it! is! now!well! established! as! a! treatment! to! induce! remission! in!
active!paediatric!CD.! !Although!initial!studies!used!elemental!formula,!further!studies!
have! since! shown! that! the!more! palatable! polymeric! diet! is! just! as! efficacious! [165]!
[166]![159].!!Despite!this,!the!pattern!of!EEN!use!differs!considerably!worldwide.!!EEN!
is! the!most!commonly! therapy! to! induce! remission! in!newly!diagnosed!children!with!
CD! in! the!UK,!with!CS! treatment! given! in! cases!of! nonSresponse! [167].! ! The! same! is!
seen!in!many!other!European!countries,! including!Sweden![168]!and!the!Netherlands!
[169].! ! However,! an! international! survey! of! 167! paediatric! gastroenterologists!
worldwide!found!that!only!4%!of!North!American!gastroenterologists!used!nutritional!
therapy! frequently,! in! comparison! to! 62%! of!Western! European! gastroenterologists.!!
This! can!be!explained!by!differences! in!perceived!efficacy!of! EEN!between! countries!






Studies!have! shown! that!EEN! induces! remission! in!up! to!85%!of! children!with!newly!
diagnosed!CD![173S176].!One!of!the!first!studies!to!show!the!efficacy!of!EEN!treatment!
in! children!was!performed!by! Sanderson!et# al! in! London! in! 1987! [164].! ! 17! children!




normal! diet! and! high! dose! corticosteroids! (CS)! (2IU/kg/day! intraSmuscular!
adrenocorticotrophic! hormone! for! 5! days! followed! by! prednisolone! 2g/kg/day!
(maximum!30mg/day)!with!a!reducing!regimen!started!after!3!weeks),!or!EEN!with!an!
elemental!diet!for!6!weeks!followed!by!a!6!week!food!reintroduction!programme.!!This!
study! showed! that! the! disease! activity! of! the! children! in! both! groups! significantly!
improved,!with!no!difference!being!seen!between!groups!in!disease!activity!index!(as!
assessed!using!the!LloydSStill!disease!activity! index!score![177]),!ESR,!CRP!or!albumin!
concentrations.! This! demonstrated! that! elemental! diet! was! as! effective! as! CS! in!
inducing!remission!in!patients!with!active!CD!of!the!small!bowel.!!Further!studies!have!
also!confirmed!these!findings![178S180].!!
Although! EEN! has! been! shown! to! be! efficacious! in! the! treatment! of! CD,! there! is! a!
question! as! to! whether! it! should! be! used! as! the! preferred! primary! therapy! in! the!
induction!of!remission.!!In!a!Cochrane!review!comparing!efficacy!of!induction!between!
EEN! and! CS! in! both! adults! and! children,! metaSanalysis! of! 6! trials! containing! 352!
patients!in!total!(192!of!whom!received!EEN!and!160!CS,!respectively)!yielded!an!odds!
ratio!of!0.33!(95%!confidence!interval![CI]!0.21%S0.53%)!in!favour!of!CS!therapy![159].!!
However,! many! paediatric! studies! were! excluded! from! this! study! due! to! questions!
about!the!methodology!used;!a!decision!that!has!since!been!questioned![181].! ! !Two!
metaSanalyses! looking! specifically! at!enteral!nutrition! therapy! to! induce! remission! in!
children!with!CD!have!found!no!difference!in!remission!rates!between!treatment!with!
CS! and! treatment!with! EEN! [182,! 183].! !One!by!Heuschkel!et# al! [182]! examined! the!
pooled!results!of!5!randomised!controlled!trials!(RCTs)!and!two!nonSrandomised!trials,!






induction!of! remission,! comprising!of! a! total! of! 204!patients;! 100! treated!by!CS! and!
104!by!EEN![183].!!No!difference!was!found!in!remission!rates!between!those!treated!
with!EEN!or!CS!(risk!ratio!0.96!(95%!CI!0.6!to!1.14)!v!0.97!(95%!CI!0.68!to!1.4),!although!
the! authors! note! that! there! were! numerous! important! differences! in! trial! design,!
including!duration!of!treatment!(3S10!weeks),!disease!location,!disease!duration!(newly!
diagnosed!v!chronic),!additional!treatment,!method!of!administration!(oral!v!NGT)!and!






colonic! disease! [184,! 185].! ! A! study! by!Afzal!et# al! comparing! response! to! EEN! in! 65!
children!with! CD! at! different! disease! locations! found! a! significantly! lower! remission!
rate! in! the! colitic! patients! as! compared! to! patients! with! ileocolonic! or! ileal! disease!
(50%!in!the!colitic!group!compared!to!82.1%!in!the! ileocolonic!and!91.7%!in!the! ileal!
groups! respectively;! p=0.021)! [186].! ! This! finding! was! confirmed! by! endoscopy! and!
biopsy! results! where! the! colitic! group! did! not! show! the! same! postStreatment!
improvements!seen!in!the!ileocolonic!group.""One!possible!explanation!for!this!is!that!
aetioSpathogenic!mechanisms!may! differ! depending! on! disease! location,! resulting! in!





disease! location! and! response! in! 24! children! with! CD! treated! with! EEN! [173].! ! In!
addition,! a! recent! study! from! England! found! no! significant! difference! between!
remission!rates!achieved!by!children!with!isolated!small!bowel!disease!as!compared!to!
those!with! isolated!colonic!disease! (10/13! (77%)!v!15/19! (79%)! respectively,!p=0.88)!
[187].! ! In! fact,! the! lowest! remission! rate! was! noted! in! the! isolated! terminal! ileal!











proSinflammatory! cytokine! production! [188,! 189].! ! Therefore,! it! is! likely! that! it! also!
exerts!direct!antiSinflammatory!effects.!This!is!especially!likely!given!that!the!epithelial!
surface! interacts! directly! with! luminal! contents! [105]! and! contributes! to! innate!










The! immediate! beneficial! effects! of! EEN! to! growth! have! been! well! documented.!!
Indeed,! the! impact! of! EEN! has! been! described! as! occurring! only! a! few! days! into!
treatment! [136].! ! Sanderson! et# al! [164]! found! that! the! children! treated! with! an!
elemental!diet!had!a!significantly!better!HV!standard!deviation!score!(SDS)!at!6!months!
postStreatment! compared! to! children! treated! with! CS! (+0.3! (SD! 2.03)! v! S2.8! (2.5),!
p<0.05)! (Figure!1.6).! ! This!occurred!despite! similar! remission! rates!being!achieved! in!
both! groups.! ! Similarly,! a! further! study! in! England! compared! height! velocity! in! 24!




review! of! interventions! for! Crohn’s! disease! related! growth! failure! and! two! other!








































days! followed! by! prednisolone! 2g/kg/day! (maximum! 30mg/day)! with! a! reducing! regimen!
started!after!3!weeks)!or!EEN!with!an!elemental!diet! for!6!weeks!followed!by!a!6!week!food!








were! followed!up! for!a!maximum!of!7!years! (median!3!years,! range!1S7!years)!postS
diagnosis.! ! Out! of! 40! patients!who! responded! to! initial! treatment!with! EEN,! 62%!of!
patients! relapsed,!with!a!median!duration!of! remission!of!54.5!weeks! (range!4S312),!
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Figure Height velocity standard deviation score (SDS) for
chronological age in the children in the high dose steroid
group (mean -2-8) and in the elemental diet group (mean
+0.3).
previous study in children has use a control group
for comparison.6 1617 The only control trial of
elemental diet to date was performed in patients in
whom the disease presented long after adult height
had been achieved.3 Moreover, this is also the first
study in which the diagnosis has been confirmed in
all cases on strict histological criteria.18 A further
feature of the present study is that the duration of
hospital stay was the same in both groups, which
eliminates bias caused by the possible beneficial
effects of bed rest on the activity of Crohn's disease.
Flexical, used in this study because of its adequate
zinc content and appropriately low sodium content,
is a complete feed in which nitrogen is supplied in
the form of amino acids and oligopeptides. The term
elemental was adopted to describe the Mead John-
son 3200 AS formula, the prototype for Flexical.
Some workers in Europe have used a new term,
semi-elemental, to describe diets that contain oli-
gopeptides as well as amino acids; this usage has not
been adopted, however, in North America or the
United Kingdom. Like other elemental diets Flexi-
cal is free of dietary antigens, which may explain its
beneficial effect. A change in diet could produce
subtle changes, though, in the microflora of the
small intestine.
It has been suggested that the immunological
reactions that may propagate the inflammation in
Crohn's disease are altered by increased energy
intake.16 This is another explanation both for the
action of an elemental diet and for high dose
steroids as the latter can increase appetite. Measur-
ing energy intake in children who eat at school as
well as at home is unreliable and was not attempted
in the present study. In addition, as routine dietary
advice is not part of current drug treatment any
attempt to quantify energy intake accurately would
be likely to distort the simple effect of drugs alone.
The unpalatability of the elemental diet was
avoided by administering it through a nasogastric
tube. All children were taught to pass their own
tubes so that those who wished to remove them to
avoid embarrassment during school hours could do
so. No child was given the opportunity of drinking
the diet as an alternative, as previous experience
with this method had led to poor compliance. Being
unable to eat normal food for six weeks was
unacceptable to one child, however, who was
therefore not studied.
Linear growth was greater in the subjects treated
by elemental diet, but the variety of factors that
affect growth make it impossible to say whether or
not this was due to active suppression of growth by
the steroid regimen.9 Expression of height velocity
in standard deviation scores for chronological age is
valid as there is poor correlation of bone age with
height v locity in the adolescent growth spurt.
There was also no significant difference in the mean
delay in bone age between the two groups (Table 1).
In conclusion, treatment by elemental diet is
equally effective in inducing remission in Crohn's
disease of the small bowel as high dose steroids in
children. Moreover, linear growth was significantly
greater in those taking an elemental diet, indicating
that there is a short term benefit for growth. The
long term results of this treatment still need to be
evaluated. A recent study of height attainment in
children with steroid responsive nephrotic syndrome
showed that, while large doses of steroids suppres-
sed growth at the time of administration, there was
little effect on ultimate height.19 This favourable
result has not been reproduced, however, in chil-
dren with Crohn's disease on current treatment. A
long term follow up study of 66 children under 16
with small bowel disease who had been treated with
-














meaning! that! 25/40! (38%)! of! patients! did! not! relapse! during! this! time! period.! ! In!
addition,! 21/44! (47%)! of! children! started! on! EEN! did! not! receive! any! CS! during! the!
study!period.!!In!those!patients!who!did!eventually!require!CS!treatment,!their!use!was!
postponed! for! a! median! 68! weeks! (range! 6S190)! postSdiagnosis.! ! The! investigators!
found! that! the! patients!who! responded! to! EEN! had! improved!weight! z! scores! from!
presentation!to!12!months,!but!a!nonSsignificant!rise! in!z!score!for!height.! !However,!
there! is! no! longerSterm!height! data! reported.! ! A! recent! retrospective! Scottish! study!
looked!at!outcomes! in!109!patients!over! two!years! following! induction! therapy!with!











Azathiorpine! (AZA)! has! been! used! as! maintenance! therapy! in! CD! for! over! 40! years!
[195S197].!AZA!is!a!proSdrug.!!It!is!converted!to!mercaptopurine!(MP)!via!glutathioneSSS
transferase!(GST).!!The!MP!is!subsequently!metabolised!via!three!competing!pathways!





acid,! which! is! excreted! in! urine.! ! A! second! pathway! results! in! methylation! by!
thiopurineSSSmethyltransferase!(TPMT)!to!form!6Smethylmercaptopurine!(MMP).!!The!
immunosuppressive! properties! of! AZA/6SMP! are! mediated! via! the! third! metabolic!
pathway:! activation! through! the! purine! salvage! pathway! to! thioguanine! nucleotides!
(TGNs).!!These!result!in!apoptosis!and!inactivation!of!TSlymphocytes!
The! gene! for! TPMT! is! located! on! chromosome! 6p22.3! [200].! ! Inheritance! of! a!
combination!of!alleles!either! for!high!or! low!activity!determines!activity! levels! [199].!!
Low!TPMT!activity!has!been!observed!in!up!to!11%!of!the!Caucasian!population,!with!
0.3%! having! negligible! activity! [201].! ! Interracial! variability! is! also! seen,! with! on!
average! the! North! American! Black! population! having! lower! TPMT! activity! than!
Caucasians! [202].! ! The! importance!of! knowing! a!patient's! TPMT!activity! level! before!
starting! thiopurine! treatment! is! because! deficiency! causes! preferential! metabolism!
towards!TGNs,!which!can!result!in!severe!myelotoxicity.!!However,!importantly,!there!
are! also! a! cohort! of! patients! who! are! hypermethylators! ('shunters')! of! thiopurines,!
resulting! in! low! TGN! concentrations! accompanied! by! increased! MMP! [203].! ! This!
carries!an!increased!risk!of!hepatotoxicity![199].!!Another!major!side!effect!associated!
with! thiopurines! is! pancreatitis,! which! is! unrelated! to! TPMT! activity! [204,! 205].!!!!!
Patients!may!also!discontinue!its!use!due!to!other!side!effects,!including!GI!disturbance!













6SMeMP:! 6Smethylmercaptopurine;! 6MeStIMP:! 6Smethyl! thioinosine! monophosphate;! AO:!
Aldehyde! oxidase;! AZA:! Azathioprine;! GMPS:! Guanosine! monophosphate! synthetase;! GST:!
GlutathioneSSStransferase;! HPRT:! Hypoxanthine! guanine! phosphoribosyltransferase;! IMPDH:!
Inosine!monophosphate!dehydrogenase;!MP:!Mercaptopurine;! TGN:! thioguanine!nucleotide;!
TIMP:! Thioguanine! monophosphate;! TITP:! Thioinsine! triphosphate;! TPMT:! Thiopurine! SS





Markowitz! et# al! (2000)! conducted! a! prospective,! double! blind,! placeboScontrolled!
multicentre! randomised! controlled! trial! (RCT)! whose! primary! objective! was! to!
determine!whether!6SMP!decreased!the!need!for!CS!in!children!with!newly!diagnosed!
moderateStoSsevere!CD! [209].! ! The!patients! randomised! to! the!6SMP! treatment! arm!
had! lower!cumulative!CS!use!over!18!months! than! the!control!arm.! ! In!addition,! the!
relapse! rate! in! the! remitters! in! the! 6SMP! arm!was! only! 9%,! as! compared! to! 47%!of!
!
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controls! (p=0.007)! after! induction! of! remission! with! CS.! ! Other! studies! have! also!
demonstrated!the!efficacy!of!thiopurines!in!children!with!CD.!An!Italian!retrospective!
study!of!123!children!with!CD!reported!a!70%!efficacy!rate!of!azathioprine! [210].! ! In!
adults,!the!2009!Cochrane!review!concluded!that!thiopurines!had!a!positive!effect!on!
maintaining!remission.!!8!trials,!comprising!550!patients!in!total!were!included!in!this!
metaSanalysis,! 208! of! whom!were! on! AZA.! ! The! overall! remission! rate! at! 1! year! in!
patients!treated!with!AZA!was!71%!(95%!confidence!interval!(CI)!64S77%),!as!compared!
to!55%!(95%!CI!49S61%)!for!placebo![211].!!!!







and! combination! therapy,! respectively).! ! Despite! the! suggestion! that! in! the! case! of!
moderateStoSsevere! CD,! earlier! introduction! of! thiopurines! further! enhances! their!
efficacy! [216S218],! similar! findings!have!also!been! seen! in! children.! ! The! recent!RISK!
study![219]! looked!to!compare!the!effectiveness!of!early!treatment!with!antiSTNF,!as!
compared! to! early! immunomodulator! (IM)! use! in! children! with! CD.! ! 552! children!
diagnosed! between! 2008! and! 2012! at! 28! North! American! gastroenterology! centres!
were! included.! ! Three! groups! were! identified:! early! antiSTNF,! early! IM,! or! no! early!













find! any! difference! in! linear! growth! between! the! 6SMP! and! placebo! group! after! 18!
months! [209].! !The!one!study! that!has!demonstrated!either!maintained!or! improved!
height!z!scores!in!response!to!AZA!has!used!a!much!higher!dose!of!treatment!(3mg/kg)!
than! that! usually! recommended! (2mg/kg)! [221].! ! By! contrast,!multiple! studies! have!
demonstrated!the!beneficial!effects!of!antiSTNF!treatment!upon!growth,!both!using!IFX!
[222S224]! and! adalimumab! [225,! 226].! ! Indeed,! the! RISK! study! found! that! only! the!
patients! treated! with! IFX! showed! a! marked! increment! in! height! SDS! 1! year! after!
therapy.!!No!such!improvement!was!seen!in!the!thiopurine!group![219].!!One!possible!
explanation!for!this!difference!is!the!impact!of!mucosal!healing.!!AntiSTNFs!have!been!
shown! to! result! in!mucosal! healing! [222,! 227,! 228].! ! However,! this! is! not! seen!with!















Even! with! more! therapeutic! options! and! the! recognition! that! children! with! growth!
failure!require!more!aggressive!management![55],!growth!failure!remains!a!significant!























rhGH! therapy! is! already!widely! used!with! excellent! efficacy! in! children!with! growth!









allocated! to! receive! either! GH! and! CS! or! CS! alone! for! 12! weeks,! with! an! extension!
phase! of! 52! weeks! for! the! children! who! responded! well! to! GH.! ! HV! significantly!
improved!in!the!group!treated!with!GH,!with!mean!(95%!CI)!height!z!scores!increasing!
from! S1.1! (S1.6! to! S0.6)! to! S0.4! (S1! to! +0.2)! during! the! 52! week! extension! period!
(p=0.004).!!However,!it!should!be!noted!that!the!inclusion!criteria!for!the!GH!treatment!














Another! potential! treatment! for! growth! failure! in! paediatric! CD,! especially! when! a!
degree! of! GH! resistance! exists,! is! rhIGFS1.! ! Patients! with! GH! insensitivity! syndrome!
(GHIS)! have! been! successfully! managed! with! rhIGFS1! therapy.! ! Chernausek! et# al!
published!a!report!examining!the!longSterm!efficacy!and!safety!of!rhIGFS1!therapy!for!
short! children!with!GH! insensitivity! syndrome.! !Entry! criteria! included!age!>!2!years,!
height! and! circulating! IGFS1! SDS! <S2! for! age! and! gender.! ! RhIGFSI! was! administered!
subcutaneously! in! doses! between! 60S120! mg/kg! twice! daily.! The! results! were! very!
encouraging.! !Height!velocity! increased!from!2.8!cm/yr!on!average!at!baseline!to!8.0!
cm/year! during! the! first! year! of! treatment! (P<0.0001).! ! Although! HV! was! lower! in!
subsequent!years,! it!still! remained!above!baseline!for!up!to!8!years! [236].! !The!main!
adverse! effect! seen! with! treatment! was! hypoglycaemia,! followed! by! injection! site!





There! have! been! no! studies! on! the! effect! of! rhIGFS1! treatment! in! children!with! CD.!!
However,! it! has!been!used! in! an! animal! study.! ! Rats!with! TNBSSinduced! colitis! grow!
poorly.! This! is! associated! with! increased! circulating! ILS6! levels! and! low! IGFS1.!!
Exogenous! IGFS1! given! to! these! rats! significantly! enhanced! their! growth! (p<0.0001)!
[123].! This! did! not! occur! as! a! result! of! a! reduction! in! the! severity! of! intestinal!
inflammation!or! improvement! in!nutritional!status! in!the!treated!group.! !However,! it!
must!be!noted!that!these!rats!still!did!not!grow!as!well!as!the!healthy!controls.!!
Restoring!IGFS1!levels!in!children!with!CD!who!may!have!some!endogenous!production!
is!not! straightforward,!because!high! levels!of! IGFS1!might!be!harmful.! ! Patients!with!
acromegaly! who! have! very! high! concentrations! of! GH! and! IGFS1,! maintained! over!
decades,! have! double! the! incidence! of! colon! cancer! [238,! 239].! ! Although! the! exact!
pathogenesis!of! this! is!unknown,! it! is! thought!to!be!directly! related!to!this!sustained!
increase! in!GHSIGFS1,! either!by! facilitating! the! growth!of!preSexisting! tumours,! or!by!
initiating!their!development![240,!241].!!This!is!an!important!consideration!in!children!
with!CD,!as!inflammation!is!also!a!risk!factor!for!intestinal!cancer.!!Therefore,!for!rhIGFS





Mathematical! and! simulation! modelling! have! long! been! used! in! industries! such! as!
aeronautics! to! design! and! develop! products! more! efficiently! [242].! ! They! are! now!




development! [243S246].! ! Population! pharmacokinetic! (PPK)! models! can! be! used! at!
each! stage! of! drug! development! [247].! ! They! enable! drugSdosing! regimens! to! be!
individualised! to! a! patient! based! upon! specific! patient! parameters! (e.g.! disease!
activity)! [248S250].! ! This! is! of! particular! use! in! drugs! that! may! be! harmful! in!
concentrations! above! the! therapeutic! range.! ! It! is! also! very! useful! in! patient!
populations!in!whom!the!number!of!samples!to!be!collected!per!patient!is!limited!due!
to!medical! and! ethical! reasons,! such! as! critical! care! patients! and! oncology! patients!
[248,!251,!252]!!
Within! paediatrics,! PPK! models! are! being! increasingly! used,! most! commonly! in! the!
area!of! oncology! [253S256].! ! For! example,! an!American!PPK! study!has!been!used! to!
recommend! a! piperacillin/tazobactam! dosing! regimen! in! children! with! febrile!
neutropenia![253].!!In!addition,!PPK!models!are!being!increasingly!used!in!other!areas!
of!paediatrics,!such!as!HIV!medicine![257],!and!determining!medication!dosages!postS















The! importance! of! promoting! growth! in! children! with! CD! is! well! recognised,! as!
demonstrated!by!its!inclusion!both!in!the!Paediatric!Crohn's!Disease!Activity!Index,!and!
the!new!Paris!disease! classification.! ! In! the!new!ECCO! /!ESPGHAN!guidelines! for! the!
management! of! paediatric! IBD,! poor! growth! has! been! clearly! stated! as! a! poor!
prognostic!factor.!
The! recent! years,! there! has! been! considerable! progress! in! our! knowledge! of! the!
underlying!mechanisms!causing!this!growth!impairment.!!Whereas!growth!failure!was!
Initially! thought!to!be!purely!a!result!of!undernutrition,!we!now!understand!that!the!
interplay! between! proSinflammatory! cytokines! and! the! GH/IGFS1! axis! also! has! an!
impact.!!The!importance!of!mucosal!healing!both!for!disease!progression!and!growth!is!
now!appreciated.!
However,! despite! these! advances! in! our! knowledge,! and! increases! in! our! treatment!
repertoire,! linear! growth! retardation! remains! a! significant! problem! for! children!with!
CD,!with!many!children!still!not!achieving!their!growth!potential.!!This!introduces!two!
important! questions! into! our! management! of! children! with! CD! and! growth! failure:!










My! overSarching! hypothesis! was! that! in! children! with! CD,! when! inflammation! is!
























induction! of! remission! with! exclusive! enteral! nutrition'),! I! hypothesised! that!
children! who! entered! complete! remission! following! treatment! with! EEN! would!
show!better! growth!over! a! 5! year! followSup!period! than!nonSresponders,! due! to!
the!presence!of!a!sustained!CS!free!clinical!remission!and!better!clinical!outcomes.!
!
To! study! this,!we! identified!a! cohort!of! children!newly!diagnosed!with!CD!at!our!
centre! between! 01/01/2003S31/12/2008! that! received! EEN! as! induction! of!
remission! therapy,! and! had! 60! months! of! followSup! data! available.! ! Data! was!
compared!between! responders! to!EEN!and!nonSresponders!at! the! following! time!
points:! 0,! 1! and!5! years.! ! To! complete! this! study,! I! first! examined! the! tolerance,!




Aim!2:! To! assess! the! efficacy! of! EEN! in! the! induction! of! remission! in! these!
children.!









3. Third,! in! section! 5.0! ('Response! of! Crohn's! disease! activity! to! thiopurines! and! its!
































Aim!1:! To!assess!baseline! IGFS1!and! IGFBPS3! levels! in! children!with!active!CD!
and!faltering!growth.!
Aim!2:! To!assess!the!tolerance!of!children!with!active!CD!to!rhIGFS1.!


































































































Data! at! diagnosis! from! children! diagnosed! with! CD! between! 2006! and! 2011! were!
retrospectively! collected.! ! All! children! were! diagnosed! at! Barts! and! The! London!




Porto! criteria! were! used! for! diagnosis! [46].! ! Data! were! collected! from! The! Royal!
London! Hospital! Inflammatory! Bowel! Disease! database! (InfoFlex),! electronic! patient!
records!(EPR)!and!patient!notes.! !The! InfoFlex! IBD!Patient!Management!System!is!an!
informationSprocessing!tool!that!was!specifically!designed!for!the!modelling!of!patient!
care!pathways.!!Data!were!inputted!in!to!InfoFlex!by!clinicians!at!the!time!of!a!patient’s!
hospital! visit.! ! A! later! version! was! developed! in! collaboration! with! the! IBD! Registry!
Board!in!order!to!collect!data!for!the!UK!IBD!Registry.!This!is!available!to!all!trusts!and!
boards! across! the!UK.! ! This! allows! the! data! collected! for! IBD! to! be! shared!with! any!
other! clinical! specialities! within! the! trust! or! board! already! using! InfoFlex! (e.g.!





as! enabling! automated! uploading! of! anonymised! data! to! the! national! IBD! Registry!
[263,!264].!!!
All! data!were! arranged! and! processed! for! handling! using!Microsoft™!Office! Excel! in!
compliance!with!the!Barts!Health!NHS!Trust!information!governance!regulations.!
The! demographic! data! collected! for! this! component! of! the! thesis! included:! age! at!
diagnosis,! ethnicity! and! gender.! ! Disease! location! was! defined! using! the! Montreal!
classification![48]!as!the!Paris!classification!had!not!been!published!when!the!research!
was! begun! [49].! ! Details! of! systemic! markers! of! disease! activity! (Erythrocyte!
Sedimentation! Rate! (ESR)‚! CSReactive! Protein! (CRP),! platelet! (PLT)! count! and! serum!
albumin! (Alb))! were! also! collected.! ! Each! patient! had! his! or! her! Pediatric! Crohn's!
Disease!Activity! Index! (PCDAI)!calculated.! !The!PCDAI! is!a!validated! index!of!a!child's!





The! term! 'auxology'!derives! from!the!Greek! '! let! it! grow'.! ! It! refers! to! the! science!of!
somatic! growth! and!development! [265].! ! In! our! study,! height! and!weight! data!were!
taken!from!the!patient's!first!visit!to!the!hospital,!either!in!the!outpatient!department!
or,! in! the!case!of!admission,!as!an! inpatient!on!the!ward.! !They!were!assessed!using!
standard! anthropometric! techniques! on! calibrated! scales.! ! Weight! was! measured!
without!shoes!on!and!wearing!light!clothing.!!Height!measurements!were!taken!using!a!






parallel! to! the! floor,!arms!by! the! sides!of! their! trunks!with!palms! flat!on! thighs,!and!
shoulders!levels.!!The!back!of!the!head,!scapulae,!buttocks!and!heels!were!against!the!
vertical! backboard!of! the! stadiometer! (see! Figure!2.1).! !Height! and!weight!data!was!
















Statistical! analysis!was! performed! using! SPSS! (version! 20;! SPSS! Inc,! Chicago,! IL)! and!
Prism!(version!5;!GraphPad,!San!Diego,!CA)!software.!!Categorical!data!was!compared!
between!groups!using! the!chiSsquared! test,!unless!more! than!25%!of!cells!contained!
counts!of!5!or!less,!in!which!case!the!Fisher’s!Exact!test!was!used.!!
Continuous! data! are! presented! as!means! ±! SD! or!medians! and! interquartile! ranges!





normally! distributed.! ! Continuous! parametric! data! were! compared! between! groups!
using!a!Student’s! tStest.! !NonSparametric!data!were!analysed!using!Mann!Whitney!U!




appropriately! transformed! prior! to!model! inclusion.! A! General! Linear!Model! (GLM),!
specifically! analysis! of! covariance! (ANCOVA),! was! used! for! multivariate! analysis! in!
order!to!describe!associations!between!a!dependent!variable,!such!as!time!to!diagnosis!









independent)! and! y! (dependent,! outcome).! ! Simple! linear! regression!was! used!with!
parametric! data.! Alternatively! a! nonSlinear! regression! model! was! used! with! nonS
parametric!data.!!
Correlation! analysis! is! concerned!with!measuring! the!degree!of! association!between!





















This! was! a! retrospective! study! conducted! to! determine! the! short! and! long! term!
outcomes! of! using! exclusive! enteral! nutrition! (EEN)! to! induce! remission! in! children!
with! newly! diagnosed! CD,! and! to! examine! the! resultant! effects! upon! linear! growth.!!
Data!were! collected! at! the! following! time! points:! at! diagnosis! (i.e.! baseline),! at! the!




Data! was! collected! retrospectively! from! The! Royal! London! Hospital! Inflammatory!
Bowel! Disease! database! (InfoFlex! see! 2.1.1),! electronic! patient! records! (EPR),! clinic!
letters! and! inpatient! notes.! ! The! data! collected! for! this! study! included! demographic!




escalations! were! recorded.! As! the! patients! included! in! this! study! were! diagnosed!
before!the!publication!of!the!Paris!classification![49],!disease!phenotype!and!location!










the! criteria! for! transition! to! the! young! adult/transitional! clinic! is! that! patients! have!
reached!their!final!adult!height!before!the!time!of!transfer.!!The!study!end!point!was!
defined!as!the!followSup!visit!at!the!end!of!5!years!from!the!time!of!diagnosis.!








up! period.! ! All! children!were! diagnosed! using! standard! endoscopic,! radiological! and!
histological!diagnostic!criteria.! !As!all!of! the!children!were!diagnosed!between!2003S

















Children! who! were! started! on! treatment! to! induce! remission! prior! to! transfer! of!
management! to!Barts!and!The!London!Hospital! for!Children!were!excluded! from!the!
study.! ! Other! exclusion! criteria! were:! use! of! medications! to! induce! remission! at!
diagnosis! other! than! EEN! or! CS! (e.g.! antibiotics! or! 5Saminosalicylates! alone),! the!
presence!of!coSmorbidities!affecting!growth!(for!example!Turner's!syndrome,!chronic!
renal!failure),!use!of!immunosuppressive!agents!for!other!coSmorbidities,!and!transfer!












the! treating!physician's!decision! to!escalate! treatments! to! immunosuppressive!drugs!
should!it!be!felt!the!patient!required!this.!
The! EEN! prescribed!was!Modulen®! (polymeric! formula,! Nestle,! UK,! see! Appendix! 4)!
given! exclusively! as! the! sole! nutritional! source! for! a! period! of! 6! weeks.! ! Up! to! a!
teaspoon! of! Nesquik®! (Nestle,! UK)! was! added! to! each! cup! to! improve! palatability.!
Other! than! this,!water,! sugar! free! chewing!gum!or!mints!were! the!only!other! things!
allowed.! ! We! encouraged! patients! to! take! EEN! orally,! but! if! there! were! concerns!
regarding! inadequate! intake,! nasogastric! (NG)! feeding! was! instigated! early.! ! Daily!
volumes! of! formula! were! prescribed! based! upon! the! child’s! estimated! energy!
requirement!(EER),!aiming!for!120%!EER!in!a!newly!diagnosed!patient![55].!!The!EER!for!
our!patient!sample!was!between!1800!S!3300!Kilocalories,!depending!upon!the!child's!
age! and! gender. The! standard! concentration! of!Modulen! is! 1kcal! /ml,! therefore! the!
volume! required! was! 1.8! –! 3.3! L/day,! according! to! the! child’s! requirements.! ! The!
Modulen®!program!at!The!Royal!London!lasts!10.5!weeks!in!total:!3S4!days!in!hospital!
for!establishment!of!EEN!feeding,!6!weeks!of!exclusive!Modulen®!and!then!a!four!week!
weaning!period!with! food! reintroduction.! !A!normal!diet!was!gradually! reintroduced!
with!one!type!of!food!reintroduced!every!two!days!and!concomitant!slow!reduction!of!
formula!volumes.!!The!formula!was!reduced!at!a!rate!of!250S500ml/week.!!A!paediatric!
dietician,!who!would!meet!with! the! patient! at! regular! intervals,! oversaw! this!whole!








PGA! is! the! scale! (inactive,! mildSmoderate,! moderateSsevere)! based! on! the! clinical!
assessment!of!the!physician![56,!269].!!At!the!end!or!shortly!after!the!cessation!of!EEN,!
patients!were!defined!as!responders!or!nonSresponders.! !Those!who!were!classed!as!
having! inactive!disease!at! this! time!were!defined!as! responders,!whereas! those!with!
mild,! moderate! or! severe! disease! were! categorised! as! nonSresponders! to! EEN.!!
Paediatric! Crohn's! Disease! Activity! Index! (PCDAI)! was! also! calculated! where! all! the!
information! to!do! so!was! available.! ! There! is! a! strong! correlation!between!PGA!and!
PCDAI![56].! !Relapse!was!defined!as!an!increase!in!disease!activity,!as!determined!by!





Statistical! analysis!was!performed!using! SPSS! (version!20;! SPSS! Inc.,! Chicago,! IL)! and!
Prism!(version!5;!GraphPad,!San!Diego,!CA)!software.!!Data!are!presented!as!means!±!
SD! or!medians! and! IQR! or! ranges! as! appropriate! for! the! distribution! normality! and!
range.! ! Categorical! data! was! compared! between! groups! using! the! chiSsquared! test,!
unless!more!than!25%!of!cells!contained!counts!of!5!or!less,!in!which!case!the!Fischer’s!






KruskalSWallis!was!used!for!simultaneously!comparing!means! in!several!groups! if! the!
data!was!parametric!or!nonSparametric!respectively.!!!Paired!data!was!analysed!using!a!
paired!tStest!for!continuous!parametric!data!and!Wilcoxon!signedSrank!test!if!the!data!
was! nonSparametric.! ! Repeated!measures! were! analysed! using! a! oneSway! repeated!
measures! ANOVA! or! Friedman! test,! depending! upon! data! distribution! normality!!
Multivariate! regression!analysis! (see! section!2.1.3)!was!used! to! find!any!associations!
























known!CD! commenced!on! thiopurine! therapy! between!2007S2010,! and! its! effect! on!
linear! growth.! ! Data!was! collected! at! the! following! time! points:! at! baseline! (i.e.! the!
time!at!which!the!patient!was!stared!on!thiopurine)!then!subsequently!at!3!months,!6!
months! and! 12!months.! ! Data!was! collected! retrospectively! from! The! Royal! London!
Hospital! Inflammatory!Bowel!Disease!database!(InfoFlex!see!2.1.1),!electronic!patient!
records!(EPR),!clinic!letters!and!inpatient!notes.!!!
The! data! collected! for! this! study! included!demographic! details,! disease! location! and!
behaviour,!serial!measurements!of!height!and!weight,!disease!duration!at!initiation!of!
thiopurine,! dose!per! kg!of! azathioprine!used,! and!any! concomitant!medical! therapy.!!!
Systemic!markers!of!disease!activity!(ESR,!CRP!and!PLT)!was!also!included,!as!were!FBC,!!
and!ALT.!!MCV!was!also!collected!as!it!has!been!reported!that!increases!in!MCV!can!be!
used! as! an! indicator! of! 6STGN! levels! [270].! ! If! the! data! was! available! to! do! so,! the!
PCDAI!was!calculated!(Appendix!1).!!!
Thiopurine!methyltransferase! (TPMT)! levels!were! collected! for! each! patient.! ! This! is!
due!to! the! fact! that!once!AZA! is!converted!to!6SMP,! it!can!then!go!down!2!separate!
pathways,! either! being! inactivated! by! TPMT,! or! activated! to! cytotoxic! 6Sthioguanine!




population! has! a! reduced! TPMT! activity! (10S26! units/ml/RBC),! and! 0.3%! of! the!
population!has!a!true!deficiency!(<10!units/ml/RBC).!!Deficiency!or!reduced!activity!of!




TGN! allows! clinicians! to! determine!whether! lack! of! response! to! treatment! is! due! to!
suboptimal!dosing!(including!as!a!result!of! lack!of!compliance)!or!nonSresponsiveness!
to!medication.!!The!normal!therapeutic!range!for!6STGN!levels!is!200S400!pmol/RBC!x!
108,! with! lower! levels! indicating! either! nonScompliance! or! under! dosing! [208,! 272,!
273].!!However,!the!ability!to!measure!6STGN!levels!at!our!unit!was!not!available!at!the!
time!of!this!study.!!!
CS! usage,! both! at! baseline! and! over! the! 12Smonth! study! period,!was! also! recorded.!!
Disease!phenotype!and!location!was!stratified!according!to!the!Montreal!classification!
[48].!!The!primary!outcomes!were!the!patients’!clinical!response!to!thiopurine,!and!its!
subsequent! impact! upon! height! SDS.! Height! was! assessed! using! standard!
anthropometric! techniques,! and! was!measured! on! the! same! calibrated! scales! upon!
each!child's!visit!to!the!outpatient!department!(see!auxology:!2.1.2).!!Height!data!was!
converted! to! standard! deviation! (SDS)! scores! using! an! auxology! SDS!
calculator.Secondary!outcomes!recorded!were:!primary!intolerance!requiring!cessation!





In! our! centre,! no! patient! is! started! on! antiSTNF! therapy! without! also! being! on! a!
thiopurine.! ! Therefore,! it! was! not! possible! to! study! the! effects! of! antiSTNF! use!
independently.! ! In! patients! who! also! received! antiSTNF! therapy,! height,! weight,!
inflammatory!markers!and!PGA!was!collected!at!the!start!of!antiSTNF!treatment,!and!
then!again!at!12!months.! !Where! the! information! to!do! so!was!available,! the!PCDAI!
was!also!calculated!at!0!and!12!months.!!!





The! study! population! consisted! of! paediatric! patients! with! known! CD! attending! the!
Children'! IBD! clinic! at! Barts! and! The! London! Children! Hospital.! ! All! children! were!















The! London! Hospital! for! Children! were! excluded! from! the! study.! ! Other! exclusion!
criteria!were:! ! initiation! of! thiopurine! or! other! immunosuppressive! agents! for! other!
nonSCD! illnesses,! the! presence! of! coSmorbidities! affecting! growth! (for! example!






the! following! time! points:! 0,! 4,! 6,! 8! and! 10!weeks,! 2!months,! 3!months! and! then! 3!
monthly! afterwards,! unless! the! treating! physician! decided! that! they! were! needed!













The! response! to! thiopurine!was! assessed! using! Physician's! Global! Assessment! (PGA)!
[56]..! ! The! PGA! was! assessed! at! baseline,! and! then! again! at! 3,6! and! 12! months.!!
Response!was!defined!as!CS!free!PGA!of!inactive!disease.!!Where!the!information!was!






Statistical! analysis!was! performed! using! SPSS! (version! 20;! SPSS! Inc,! Chicago,! IL)! and!
Prism!(version!5;!GraphPad,!San!Diego,!CA)!software.!!P!values!<0.05!were!considered!
significant.! ! Data! are! presented! as! means! ±! SD! or! medians! as! appropriate! for! the!
distribution! normality.! ! Continuous! data! were! compared! between! groups! using! an!
Student’s! tStest! for! parametric! data,! and!Mann!Whitney! U! tests! for! nonSparametric!
data.! ! CRP,! ESR,! PCDAI! and! height! SDS! were! analysed! using! a! oneSway! repeated!
measures! ANOVA! or! Friedman! test,! depending! upon! data! distribution! normality.!!
Paired!data!was!analysed!using!a!paired! tStest!or!Wilcoxon! signed! rank.! ! Categorical!
data! were! compared! between! groups! using! chiSsquared! test! or! Fishers! Exact! test.!!
Multivariate!analysis!was!used!to!find!any!associations!between!factors!(including!age,!












2.4!! Mathematical! modelling! to! restore! circulating! IGFE1!






day! doses! of! rhIGFS1! (120µg/kg! per! dose)! given! by! subcutaneous! injection.! ! These!
results!were!used!to!design!a!mathematical!model! that!would!define!dosing!regimes!





8! children!with! known! CD! as! diagnosed! using! standard! endoscopic,! radiological! and!

















of! S2! SDS! according! to! the! patient's! age! and! gender,! and! evidence! of! active!
inflammation!as!demonstrated!by!either!an!erythrocyte!sedimentation!rate!(ESR)!>25!
mm/hr!and/or!a!CSreactive!protein!(CRP)!>!10!mg/l!(Table!2.1).!!PCDAI!was!not!chosen!























increase! in! IGFS1,! based! on! the! increases! in! IGFS1! seen! in! a! cohort! of! paediatric!
endocrinology! children!with!no!GI! disease! treated!with! rhIGFS1! for! growth!hormone!















Prior! to!entry! into!the!study,!all!patients!had!a! full!history!and!physical!examination,!
including!an!accurate! recording!of!height,!weight!and!assessment!of!pubertal! status,!
including!a!bone!age.!!In!addition,!they!also!had!an!electrocardiogram!(ECG)!and!faecal!





Height! measurements! were! measured! on! every! child! at! each! attendance! to! the!
outpatients! department! (see! auxology! 2.1.2).! ! Height! velocity! for! each! patient! was!


















count! (FBC),! electrolytes,! inflammatory! markers! (CRP! and! ESR),! baseline! IGFS1! and!
blood! glucose! measurement.! ! Due! to! their! importance! in! the! regulation! of! the!
bioavailability! of! IGFS1,! and! low! levels! seen! in! conditions! resulting! in! reduced! IGFS1!
levels,!IGFBPS3!and!ALS!were!also!measured![54,!82,!277].!!!
!Stool! samples! were! collected! to! measure! faecal! alphaS1Santitrypsin! (A1AT)!
concentrations! in! order! to! assess! the! presence! and! degree! of! proteinSlosing!
enteropathy![278].!!The!PCDAI!was!also!calculated.!
Each!patient!was! then! given! a! single! subcutaneous! injection!of! rhIGFS1! at! a! dose!of!
120µg/kg.!!Serial!venous!blood!samples!were!drawn!at!the!following!time!points:!0,!1,!
2,! 3,! 4,! 6,! 12,! 17! and! 24! h.! ! Blood! sugars! and! vital! signs! were! checked! regularly.!!

































A)! During! admission! 1,! patients! were! given! a! single! dose! of! rhIGFS1! (120µg/kg)! at! 0! hours.!!




























Plasma! glucose! was! determined! immediately! after! blood! sampling! (Beckman!







IGFS1! and! IGFBPS3! levels! were!measured! by! competitive! binding! radioimmunoassay!
(Esoterix!Inc.!Laboratory!Services).!!The!sensitivity!of!the!assay!for!IGFS1!was!15ng/ml!
and!the!intraSassay!coefficient!of!variation!averaged!14.1%.!!The!sensitivity!of!the!assay!
for! IGFBPS3!was! 0.3!mg/l! and! the! intraSassay! coefficient! of! variation! averaged! 13%.!!






















A! mathematical! model! for! the! administration! of! rhIGFS1,! based! on! detailed!
pharmacokinetics,!was!formed!to!allow!for!a!dosing!regimen!to!be!determined!which!
would! return! circulating! IGFS1! levels! back! to! within! the! normal! range! without!





















The!concentration!of! IGFS1! in! the!circulating!compartment! (Ac)! is!determined!by! the!
rate! of! IGFS1! synthesis! (Ksyn)! and! rate! of! clearance! (Kout).! ! Under! steady! state!
conditions,!which!we!assume! is!occurring!at!baseline,!both!values!will!be!equivalent.!!































Ksyn! was! further! scaled! with! linear! weight! due! to! its! affecting! the! volume! of!
distribution.!Other!covariates,!including!CRP,!ESR,!PCDAI!and!age,!were!tested!for!their!
impact!on!Ksyn.!!
To!check! if! the!model's!predicted! increases! in! IGFS1!accurately!compared!with! those!
actually!observed!in!our!patients!following!exogenous!dosing,!a!series!of!mathematical!
assessments! were! carried! out! in! addition! to! basic! goodnessSofSfit! plots.! ! Model!
development!used!the!NONMEM!objective!function!value!(OFV);!parameter!estimate!




fit! with! a! probability! p<0.05.! ! The! model! was! optimised! to! achieve! an! average!
concentration! of! IGFS1.! This! formed! the! basis! of! a! utility! function! and! was! used! to!
predict! the! average! concentration! (Cave)! with! a! dosing! regimen! derived! from! the!























individual! predicted! SDS! derived! from! model! predicted! CAVE;! and! ɛi! denotes! the!
individual!deviations!from!the!target.!Utility!minimised!ɛi!by!least!squares!regression.!!
The!model!was!extrapolated!to!see!how!it!would!fair!under!the!constraints!of!a!larger!
clinically! relevant! population! with! individual! variability.! This! was! achieved! by! using!
demographic!details!for!384!children!aged!8–14!years!from!the!clinical!database.!!Each!
patient!was! assigned! a! random! PCDAI! score! (from! a! uniform! distribution! 0–48)! and!
also! individual! model! parameters.! With! this! extrapolation,! the! utility! function! (a!


































was! conducted! in! accordance!with! the! Declaration! of! Helsinki.! ! All! participants! and!















The! incidence! of! paediatric! CD! is! increasing! across! all! ethnicities! [24,! 280].! ! Some!
studies!have!also!reported!a!reduction!in!the!mean!age!at!diagnosis![35].!!Childhood!is!
a! time! of! significant! physical! changes! and! emotional! maturation.! ! Therefore,! it! is!
important! that! children! with! CD! are! recognised! and! diagnosed! promptly! to! try! and!
modulate!the!impact!that!inflammation!has!on!their!growth!and!overall!development.!
Children!with!CD!often!experience!a!considerable!duration!of!time!between!the!onset!
of! symptoms!and!diagnosis.! !A!UK! study! looking!at!presenting! features!of!paediatric!
IBD!reported!that!18%!of!children!with!CD!had!a!symptom!duration!of!1S3!years,!and!
9%! symptoms! for! more! than! 9! years[42].! ! This! is! important! as! there! is! a! negative!
correlation!between!the!duration!of!symptoms!and!height!SDS!at!diagnosis![42,!101].!!
Poor!growth!is!recognised!as!a!poor!prognostic!factor!in!CD![55].!!In!addition,!although!
































diagnosis! was! negative! at! S0.23! [1.08]! (Figure! 3.2.A).! ! A! quarter! of! patients! (26.5%;!
27/102)!had!a!height!SDS!<S1!at!diagnosis,!with!8.8%!!(9/102)!of!patients!having!a!SDS!
<S2.!































































































The! commonest! presenting! symptom! was! abdominal! pain,! with! 74.6%! of! patients!
reporting! this! (Table! 3.1).! This!was! followed! by! diarrhoea! (64.8%;! 79/122)! and! then!
weight!loss!(63.9%;!78/122).!!Only!10!patients!(8.2%)!did!not!have!any!of!these!three!
symptoms,!with!38.5%!(47/122)!presenting!with!all!three.!!35.2%!(43/122)!of!patients!


































Table" 3.1! Demographics,! disease! phenotype,! behaviour! and! activity! and! presenting!






































































felt! that! the! outcome! could! be! associated! with! more! than! one! predictor! variable,!
multivariate! analysis! was! performed.! This! analysis! did! not! show! any! statistically!
significant!association!between!symptom!duration!at! !diagnosis!and!gender! (p=0.22),!
ethnicity! (p=0.18),! age! (p=0.47),disease! behaviour! (p=0.63)! or! location! (0.76)! (Table!
3.2).! ! .! ! Multivariate! analysis! found! no! association! between! symptom! duration! at!
diagnosis!and!ESR!(p=0.26),!CRP!(p=0.39)!or!PCDAI!(p=0.64).!!
Presence! or! absence! of! specific! symptoms! (diarrhoea,! abdominal! pain,! weight! loss,!
anorexia,! EIMs)!was! not! associated!with! symptom!duration! at! the! time! of! diagnosis!
(Table!3.2).!!The!presence!of!the!classic!'triad'!of!symptoms!(diarrhoea,!weight!loss!and!

















have! lower! height! SDS.! There!was! a! negative! correlation! between! time! to! diagnosis!
and!height!SDS!at!diagnosis! (r=S0.06,!p=0.02)! (Figure!3.6.A).! ! The! same!was! seen! for!
































There!was! a! statistically! significant! negative! correlation! seen! between! the! time! to! diagnosis!




















































Neither! disease! phenotype! or! behaviour,! or! the! presence! of! upper! GI! or! perianal!
disease! had! a! statistically! significant! association! with! height! SDS! at! diagnosis,! as!



















































In! our! cohort! of! paediatric! CD! patients! diagnosed! between! 2006S2011,! poor! growth!
was!very!prevalent!at!diagnosis,!with!a!quarter!of!patients!having!a!height!SDS!<S1.!!In!
a! normally! distributed! population,! 13.6%! is! the! usual! percentage! below! S1! SD.! ! The!
expected!percentage!below!S2!SD! is!2.1%.! !However,!9%!of!our!patients! fell! into!this!
category.!




comparable! to! results! of! a! study! looking! at! presenting! features! of! 739! children!
diagnosed!with! IBD! in! the! UK! between! 1998S1999! [42].! ! This! report! found! that! the!
median!time!from!onset!of!symptoms!to!diagnosis!was!5!months,!with!14%!having!had!







In! contrast! to! children!with!CD,! children!with!UC!often!experience!a! shorter! interval!
between!onset!of!symptoms!to!diagnosis! [42].! !This! is!often!speculated!to!be!due!to!




more! likely! to! present! with! symptoms! less! conducive! to! speedy! investigations! [53].!!
However,!our!study!did!not!find!any!association!between!any!specific!symptoms!and!
time! to!diagnosis.! ! This!was!even! the! case!when! children!presented!with! the! classic!
'triad'!associated!with!CD!(diarrhoea,!abdominal!pain!and!weight!loss)!were!present.!





(mean! SDS! in! our! patients! S0.23,! as! compared! to! S0.50! in! the! previous! study).!!
However,! as! has! been! previously! stated,! 25%! of! our! patients! had! height! SDS! <S1! at!
diagnosis.! ! This! is! important! because,! even! though! some! patients! show! catchSup!
growth,!a!significant!number!of!patients!remain!growth!retarded!despite!treatment!of!
their! CD! [94,! 101,! 220].! ! This! emphasises! the! importance! not! only! of! the! early!












All! patients! had! anthropometric! data! measured! on! the! same! scales,! allowing! for!
standardisation.! !This! is!of! importance!when!assessing!growth!as!different!scales!and!
assessors!can!yield!significantly!different!results![284].!!!!!!
However,!in!comparison!to!Sawczenko!et#al!(2003),!who!had!a!total!of!739!new!cases!
of! IBD!across!many!centres! in!Great!Britain!and! Ireland![42],! this!was!a!single!centre!
study.! !Therefore,!although!comparisons!may!be!drawn!against!previous!results!from!
our!centre![101],!this!cannot!be!generalised.!!Also,!as!with!all!studies!of!this!nature,!the!







Paediatric! CD! has! now! been! recognised! as! presenting! very! different! challenges! to!
those!experienced!by!our!colleagues!managing!adults.!!Disease!is!often!more!extensive!
at! diagnosis,! and! follows! an! aggressive! course! [26].! Therefore,! treatments! such! as!
immunomodulators!are!being! initiated!earlier! [217].! ! In!addition,!antiSTNF! therapy! is!
increasingly!used.!!Sawczenko!et#al!(2006)!found!that!from!91!children!diagnosed!with!
CD!before!1989,!although!height!SDS!did!overall! improve!significantly! from!diagnosis!










Although! improving,! children! diagnosed! with! CD! at! our! centre! still! experienced! a!
considerable! length!of! time!between! the!onset!of! symptoms!and!diagnosis.! ! 25%!of!
patients!had!at!least!12!months!of!symptoms!before!diagnosis.!!Impaired!growth!was!
prevalent!at!diagnosis,!with!a!quarter!of!patients!having!a!height!SDS!<S1.!!As!has!been!
demonstrated! before,! there! was! a! negative! relationship! between! the! length! of! the!
interval!between! the!onset!of! symptoms!and!diagnosis!with!height!SDS!at!diagnosis.!!
This!highlights! the! importance!of!early! recognition!of! children!with!CD,! and!also! the!


















Exclusive! enteral! nutrition! (EEN)! using! an! elemental! or! polymeric! formula! has! been!
shown!to!be!effective!treatment!for!children!with!active!CD![164].!!MetaSanalyses!have!
shown! EEN! to! be! as! effective! as! CS! in! inducing! remission! in! children! [182,! 183].! ! In!
contrast!to!CS!which!are!associated!with!adverse!effects!upon!growth![285]!and!bone!
density! [286,! 287],! EEN! has! an! excellent! safety! profile! [105].! ! Recent! guidelines!
published!by!the!European!Crohn’s!and!Colitis!Organisation!(ECCO)!and!the!European!
Society! for! Pediatric! Gastroenterology,! Hepatology! and! Nutrition! (ESPGHAN)! have!
recommended! EEN! as! the! induction! therapy! of! choice! for! children! with! CD! [55].!!
However,!despite!this,!EEN!is!not!used!as!the!therapy!of!choice!worldwide.!!Although!




term! outcomes! for! children! following! initial! induction! therapy! with! EEN.! ! One! such!
study!has!been!reported!from!a!centre!in!England![193],!and!one!from!Scotland![194].!!







been! no! studies! investigating! whether! the! children! who! do! not! respond! have! a!
different! clinical! course,! and!differing! growth!outcomes,! to! children!who! respond! to!
EEN.!!This!knowledge!is!both!useful!in!supporting!the!use!of!EEN!as!an!induction!agent,!





104! children!were!diagnosed!with!CD!at!Barts! and!The! London!Hospital! for!Children!
between!1!January!2003!to!31!December!2008.!!12!patients!received!neither!EEN!nor!
CS! upon! diagnosis! (9! received! 5Saminosalycilates! (5SASA)! and! 3! antibiotics)! and! so!
were! excluded! from! the! study.! ! A! further! 3! patients! transferred! their! care! to! other!
centres!before!the!completion!of!the!5!years.!!Therefore!15!patients!were!excluded!in!
total,!leaving!a!cohort!of!89!patients!(Figure!4.1).!!!
The!median! age! (range)! at! diagnosis!was! 12.75! (4.84! S! 15.86)! years.! ! 70.8%! (63/89)!






























































All! 89!patients!were! initially! started!on!EEN!using!Modulen®! (Nestle!UK)! as! per!unit!
protocol! (Appendix! 3).! ! No! child! was! started! on! CS! as! initial! therapy.! ! 72! patients!
(80.9%)!took!the!Modulen!orally,!with!17!(19.1%)!patients!requiring!an!NG!tube!due!to!
dislike!of! the! taste!or! inability! to! consume! the! required! amounts!per!day.! ! EEN!was!
generally!well! tolerated!with!only!5!patients! (5.6%)!unable! to! comply!with! the! full!6!
weeks!of!treatment.!!The!median![IQR]!age!of!patients!who!were!intolerant!of!EEN!was!
higher! than! those! who! tolerated! the! treatment! (13.58! [2.23]! vs! 12.75! [4.17! ]!
respectively;! p=0.02,! Mann!Whitney! U).! ! No! side! effects! were! reported! during! the!








no!response!(NR).! !The!patients!were!separated! into!two!groups!for! further!analysis:!
'responders'!and! 'nonSresponders'.! !Only! the!patients!achieving!CR!were!classified!as!










the!5!years! (3).! !The!remaining!89!patients!were!started!on!EEN.! !Following!this,!56!patients!


























that! there! were! multiple! factors! that! could! possibly! influence! whether! a! patient!
responded! to!EEN!or!not.! ! These! included!both!demographic! factors,! such!as!age!or!
gender,! as! well! as! diseaseSspecific! indices! such! as! location,! behaviour! and! activity.!!
Therefore,!a!multivariate!analysis!was!performed,!allowing!us!to!account!for!multiple!
predictor! values! simultaneously.! ! The! following! factors! were! tested:! age,! gender,!
ethnicity,!disease!location!and!behaviour,!CRP,!ESR!and!PCDAI!(Table!4.2).!!
Patients!who!did!not!respond!to!EEN!had!higher!baseline!PCDAI!scores!(mean![SD]!37.8!
[SD])! than! patients!who! responded! (mean! [SD]! 30.8! [9.7]);! p=0.005,! Student's! tStest!
(Figure! 4.3.A).! ! However,! there! was! no! significant! difference! between! CRP! (p=0.63,!
Mann! Whitney! U)! or! ESR! (p=0.20,! Mann! Whitney! U)! between! groups! at! diagnosis!
(Table!4.2).!!
There!was!no! significant! association! seen!between!disease! location! and! response! to!
EEN! (p=0.74).! ! However,! it!must! be! noted! that! as! there!were! only! 8! patients! in! the!
colonic! group,! a! type! II! error! (failure! to! reject! a! false! null! hypothesis)! may! have!
occurred.! !Also,! although!patients!with!nonSstricturing!nonSpenetrating!disease!were!
found! to! be! significantly! more! likely! to! respond! to! EEN! than! those! with! either!
stricturing! or! penetrating! disease! (p=0.001),! the! number! of! patients!with! stricturing!
(n=3)! and!penetrating! (n=11)!disease!were! low,! and! so! this! finding!may!be!due! to!a!
type! I! error! (the! incorrect! rejection! of! a! true! null! hypothesis).! ! Another! statistically!











12.96! [2.50],! p=0.03! Student's! tStest)! (Figure! 4.3.B).! ! Given! the! above! results,! we!
checked! whether! older! children! were! more! likely! to! have! perianal! disease! or!
stricturing! or! penetrating! behaviour.! ! However,! there! was! no! association! found!
between! age! and! the! presence! of! perianal! disease! (p=0.15)! or! disease! behaviour!












































A)! PCDAI! at! diagnosis! was! significantly! lower! in! responders! (mean! [SD]! 30.8! [10.2])! when!


































































































Mean!CRP!(mg/l)![SD]! 32.8![32.8]! 45.3![38.8]! 0.63!













the! responders! to! EEN! were! ! significantly! lower! than! those! in! the! nonSresponders!!
(p<0.001,!Wilcoxon!signed!rank!test)!(Figure!4.3A!and!4.3B).!
The!PCDAI! (Appendix!2)! also!decreased! in! the! group!of!patients! from!diagnosis! to!6!
weeks.! ! Paired! results! were! available! in! 67! patients.! ! The! median! [IQR]! PCDAI! at!
diagnosis!was!31.25![25.63!–!40.0],!and!5.0![2.5!–!17.5]!at!6!weeks!(p<0.001,!Wilcoxon!
signed!rank).!!!
PCDAI! at! 6! weeks! was! significantly! lower! in! responders! as! compared! to! nonS
responders!(median![IQR]!5.0![0!S!7.5]!vs!18.75![9.5!–!27.5],!p<0.0001,!Mann!Whitney!
U)! (Figure! 4.3C).! ! As! has! been! previously! described! in! other! studies! [56],! a! Pearson!
correlation! of! our! data! showed! that! there! was! a! statistically! significant! correlation!








































also! significantly! lower! in! responders! than!nonSresponders! (median! [IQR]! 8.0! [4.0! –! 16.5]! vs!
13.0! [7.0! –! 44.0],! p<0.0001).! ! C)! PCDAI! median! [IQR]! at! 6! weeks! was! 5.0! [0.0! –! 7.5]! in!


















































mildSmoderate! or! moderateSsevere! disease),! with! changes! in! symptoms! and/or!
necessitating! an! escalation! in! the! onSgoing! therapy.! ! There! was! no! significant!
difference! between! the! time! spent! in! remission! between! responders! to! EEN! (mean!




























(76.8%)! and! 27! of! 33! (81.8%)! patients! in! the! responder! and! nonSresponder! groups,!
respectively.! ! There!was! no! significant! difference! in! the! number! of! patients! starting!





























Azathioprine! 43!(76.8%)! 27!(81.8%)! 0.79!
AntiSTNF! 18!(32.1%)! 11!(33.3%)! 0.68!









ANOVA! analysis! was! performed! on! these! patients.! ! We! found! that! in! this! overall!
cohort,!there!was!no!improvement!of!growth!over!the!5!years.!!The!mean!height![SD]!









A)!The!mean![SD]!height!SDS!at!diagnosis!was! S0.29! [1.22].!B)!There!was!no! improvement! in!
height! SDS!over! the!5! years.! ! The!mean!height! [SD]! SDS!at! diagnosis!was! S0.28! [1.23],! S0.33!
[1.23]!at!1!year,!and!S0.29![1.21]!at!5!years!(p=0.78).!Mean!and!SD!indicated!by!error!bars.!!!!



















































































Responders! to! EEN! had! significantly! greater! increases! in! height! SDS! than! nonS
responders:! A)! From! diagnosis! to! 1! year! after! followSup.! ! The!mean! [SD]! change! in!
height! SDS!was!+0.05! [0.39]! as! compared! to! S0.23! [0.39]! in!nonSresponders! (p=0.01,!
Student!TStest).!!B)!From!diagnosis!to!the!end!of!the!5!years.!!The!mean![SD]!change!in!








































































































Within! the! cohort! of! 89! patients,! multivariate! analysis! showed! that! there! were! no!
factors! present! at! diagnosis! that!were! significantly! associated!with! change! in! height!
SDS! at! 1! year! (Table! 4.4).! !However,! there!was! an! association! seen!between!CRP! at!
diagnosis! (p=0.035)! and!ESR! at! diagnosis! (p=0.045)! and! change! in! height! SDS!over! 5!
years! (Figure! 4.8).! ! There!was! no! such! relationship!with! PCDAI! at! diagnosis! (p=0.29)!
(Figure!4.5.C).!
!














































































































Taking! the! responders! alone,! a! statistically! significant! correlation! was! again! seen!
between!the!CRP!at!diagnosis!and!poor!growth,!as!defined!by!changed!height!SDS!(r=S
0.29,! p=0.05).! ! However,! there! was! no! statistically! significant! correlation! between!
raised!ESR!at!diagnosis!and!change!in!height!SDS!(r=0.03,!p=0.45).!!Using!multivariate!
analysis,! there!were!no!significant!associations! found!with!any!of! the!other!variants,!






29!patients! (32.6%)!out!of! the!56!responders!did!not! require!any!CS!over! the!5!year!





months.! ! However,! a! longer! duration! of! time! to! the! start! of! CS! did! not! result! in!
improved! growth! (Figure! 4.9)! (r=0.19,! p=0.35,! Spearman),! nor! was! there! any!











not! require! any! CS! during! the! 5! year! study! period.! ! However,! there! was! no! statistically!






was! a! significant! improvement! in! weight! SDS! at! 1! year! (mean! [SD]! at! 1! year! S0.24!
[1.36];!p<0.001,!paired! tStest,!which!was! sustained!over! the!5!years! (mean! [SD]!at!5!
years! S0.24! [1.39];! p<0.001,! oneSway! repeated! measure! ANOVA)! (Figure! 4.10.B).!!
However,! there!was!no!difference!between!change! in!weight!SDS! in! responders!and!
nonSresponders! to! EEN,! either! at! 1! year! (mean! [SD]! +0.41! [0.09]! vs! +0.47! [0.17],!
respectively;!p=0.77)!!or!after!5!years!(mean!change!in!weight!SDS![SD]!in!responders!
+0.58! [0.13]! vs! +0.24! [0.24]! in! nonSresponders;! p=0.17)! (Figure! 4.11).! ! As! expected,!



































































A)! The! median! weight! SDS! at! diagnosis! was! S0.84! (range! S3.53! to! +2.86),! mean! [SD]! S0.68!























































































































One! of! the! commonest! reasons! given! for! not! using! EEN! as! induction! therapy! are!
concerns!about!compliance![170].!!However,!around!95%!of!the!children!in!our!study!
completed! the! 6! week! course! of! EEN.! ! This! is! a! similar! percentage! to! that! seen! in!
previously! published! data.! ! Indeed,! compliance! greater! than! 90%! is! often! described!




























193],! it! is! similar! to! the! findings! of! a! recent! study! from! Scotland,!which! reported! a!
remission!rate!of!60%!in!109!newly!diagnosed!children!with!CD!treated!with!EEN![194].!!
It!has!to!be!noted!that!all!of!the!children!in!our!study!were!prescribed!EEN!as!induction!
therapy.! ! Therefore,! we! have! no! way! of! knowing! whether! similar! remission! rates!
would!have!been!seen!following!CS!therapy.!!However,!two!metaSanalyses!comparing!














no! significant! correlation! between! age! and! either! of! these! factors.! ! Adult! studies!







treatment.! !However,!overall! tolerance!was! till! 95%,!and!as! there!were! such!a! small!
number!in!the!intolerant!group,!we!cannot!draw!conclusions!from!this.!!!!!
Unfortunately,! there! are! few! reports! available! from! other! studies! with! which! to!
compare!our!results!to,!to!help!ascertain!whether!age!was!a!common!factor!associated!
with! response.! ! Knight! et# al! (2005)! found! that! nonSresponders! to! EEN! had! a! lower!
median!age!at!diagnosis!(median![range]!9.2![6.6S14]!years!as!compared!to!12.6![7.7S
15.8]!years!in!responders).!!However,!the!numbers!from!this!study!were!low,!with!only!
4! patients! in! the! nonSresponder! group,! and! 44! patients! in! total! [193].! ! It! would! be!
interesting!to!be!able!to!review!the!ages!of!patients! from!other!studies! investigating!
response!of!children!with!CD!to!EEN,!but!these!are!not!available!to!us.!!Therefore,!we!
recommend! that! age! is! considered! when! performing! future! studies! regarding! the!
effectiveness!of!EEN.!
In! our! cohort! of! patients,! multivariate! analysis! found! that! PCDAI! was! significantly!
associated!with!response.!!Children!with!higher!PCDAI!scores!were!less!likely!to!go!into!
complete! remission! with! EEN.! ! However,! our! results! also! found! that! children! with!
perianal!disease!on!average!had!a!higher!PCDAI!on!diagnosis;!a!fact!most!likely!due!to!
the! inclusion!of!perianal!disease!assessment! in! the!calculation!of! the!disease!activity!
index! [56].! !Therefore,! the!presence!of!perianal!disease!may!explain!our! findings.! ! In!
addition,! similar! to! the!question!of! response,! it! is! important! to! remember! that!all!of!
our! patients! had! EEN! as! induction! therapy! at! diagnosis,! and! so! there! is! no! other!





Many! studies! have! demonstrated! the! beneficial! effects! of! EEN! to! growth! over! the!
short!term![133,!164].!!EEN!is!known!to!cause!mucosal!healing,!decrease!inflammatory!





growth!than!nonSresponders,!and!that! this!was!maintained!over! the!5!years! (Figures!
4.6)!.!!This!occurred!despite!no!differences!in!time!to!relapse!(Figure!4.4)!or!treatment!
escalation! between! the! groups.! In! addition,! although! increased! weight! was,! as!
expected,! significantly! correlated! with! better! growth,! there! was! no! significant!
difference!in!weight!gain!between!responders!and!nonSresponders!to!EEN.!!!!Of!note,!
our! study! followed! up! both! responders! and! nonSresponders! over! the! 5! years.! ! If!
investigated! in! isolation,! our! responders! showed! a! significant,! but! relatively! small!
mean!change!in!height!of!+0.18!SDS!over!5!years!(Figure!4.7.A).!!However,!this!figure!is!
more! striking!when! compared! to!nonSresponders,!whose!height! SDS!decreased!by! a!




with!higher! scores! correlating! to!no! response.! ! Therefore,! a!possible!explanation! for!
the! poor! growth! in! the! nonSresponders! could! be! that! they! had!worse! inflammation!









been! treated! with! CS! during! our! study! period,! and! those! who! had! not.! ! This! is! in!
contrast! to! the! findings! of! other! studies.! ! However,! these! studies! often! compare!
growth! in! children!with! CD! treated!with! CS! as! compared! to! those! treated!with! EEN!
[156,!164,!174]!or!contain!patients!with!a!longer!duration!CS!use![220].!!In!our!study,!

















CD! treated! with! EEN! as! induction! therapy.! ! All! of! the! children! in! the! study! had! 60!
months!of!data!available.!!Data!was!analysed!at!specified!time!points!in!each!patient.!!
At!Barts!and!The!London!Hospital!for!Children,!children!with!newly!diagnosed!CD!are!
all! started! on! EEN! instead! of! CS,! regardless! of! age,! disease! activity! or! disease!
phenotype.! ! This! allowed! us! to! investigate! the! shortS! and! longSterm! effects! in! a!
heterogeneous! cohort! of! patients.! ! In! addition,! in! contrast! to!other! studies,!we!also!
collected! 5! year! data! on! the! nonSresponders! to! EEN! in! order! to! compare! how! their!
disease! progressed! over! time.! ! Whereas! the! short! term! differences! between!
responders!and!nonSresponders!to!EEN!have!been!described!before,!this!has!not!been!
conducted!over!a!period!of!years!previously.!!We!were!able!to!show!that!response!to!
EEN!was!associated!with!better!growth,!even! if! it!had!no! impact!on!other! longSterm!
outcomes,!such!as!surgery!rates!or!time!in!remission.!
However,!this!was!a!retrospective!study.!!Therefore,!data!collected!for!this!study!was!
completely! dependent! upon! clinical! notes! and! electronic! records.! ! Unfortunately,!
information!was!missing!for!some!patients!at!some!time!points.!!Also,!although!there!
was! a! standardised! protocol! for! EEN! therapy! and! subsequent! food! reintroduction,!
other! treatments!were! instigated! at! the! treating! physician's! discretion.! ! In! addition,!
although!we!did!have!a!very!varied!cohort!of!patients,!this!study!was!conducted!at!a!












through! to! final! height,! allowing! for! standardised! assessments! at! standardised! time!
points.!!This!would!minimise!the!amount!of!missing!data.!
The!study!raises!two!important!questions:!first,!why!do!some!patients!respond!to!EEN!
and! others! not?! ! In! our! study,! we! found! that! younger! age! was! associated! with!
response,! something! that! has! not! been! reported! before.! ! We! also! found! that! our!
patients!who!were!intolerant!of!EEN!had!a!higher!mean!age!than!those!who!tolerated!
the!treatment.!!However,!as!we!had!only!5!children!who!were!unable!to!tolerate!the!
EEN,! this! may! have! been! an! incidental! finding.! ! A! prospective! multicentre! study!
containing!a!wide!age!range!of!patients!would!help!determine!whether!age!is,!indeed,!
a! factor! related! to! response! to! EEN,! and!whether! this! is! in! part! due! to! problems!of!
tolerance.!
Secondly,!although!we!have!an!idea!as!to!why!treatment!with!EEN!improves!growth!in!










In! our! cohort! of! patients,! we! found! that! younger! children,! and! children!with! lower!
PCDAI! scores!were!more! likely! to! respond! to! EEN.! Response! to! EEN!was! associated!
with! improved! growth,! which! was! sustained! over! the! 5! year! study! period.! ! This!
occurred!despite!no!significant!difference!between!time!spent!in!remission,!CS!use!or!
treatment! escalation! in! each! group.! ! This! study! provides! further! evidence! of! the!


























This! includes!an!American! randomised!controlled! trial!performed!by!Markowitz!et#al!
[209]! which! found! that! following! induction! of! remission! with! CS,! relapse! rates! in!
patients! in! the! 6SMP! arm! were! only! 9%,! as! compared! to! 47%! in! the! placebo! arm.!!
However,!in!recent!years,!the!efficacy!of!thiopurines!has!been!questioned.!!Indeed,!a!
recent!paediatric! study! found!no! statistically! significant!difference! in! remission! rates!
between! those! treated! with! early! immunomodulators! as! compared! to! no!
immunotherapy!use!at!all![219],!while!recent!studies!in!both!adults![215]!and!children!
[219]!have! found! that!antiSTNF!use! is! superior! to! thiopurine!use! in!newly!diagnosed!








[222,! 293],! no! study! has! demonstrated! a! beneficial! effect! of! either!AZA!or! 6SMP!on!
growth! in! children! with! CD! [220],! even! when! the! thiopurine! was! efficacious! at!
maintaining!remission![209].!!This!is!a!surprising!finding.!!Given!that!proSinflammatory!
cytokines!have!been!shown!to!have!a!direct!impact!upon!growth!in!children!with!CD,!
both! through!anorexigenic!effects! [119,!120],!and!direct!action!on! the!GH/IGFS1!axis!
[89],! any! therapy! that! results! in! suppression! of! inflammation!without! the! use! of! CS!
could! be! expected! to! cause! improvement! in! growth.! ! One! possible! explanation! for!




















AZA!was! 12.70! (6.65! S! 16.71)! years,!with! a!median! (range)! disease! duration! of! 0.97!
(0.07! S! 6.38)! ! years! at! initiation! of! therapy! (Figure! 5.1! The!mean! starting! dose! was!




































































































15! of! the! 58! patients! (26%)! followed! up! for! 1! year! had! adverse! reactions! to!
azathioprine:!4!patients!developed!transaminitis,!6!lymphopenia,!2!raised!amylase!and!
3!headaches.! !The!3!patients!with!headaches!were!switched!to!6SMP,!which!resolved!
these! symptoms! in! 2! of! the! patients.! ! From! the! 58! patients,! 7! patients! ! (12%)!
discontinued!therapy!within!the!year's!followSup!period:!4!due!to!lymphopenia,!2!due!
to!raised!amylase!and!1!because!of!headaches..! !The!ability! to!measure! levels!of! the!



















year.! !At!3!months,!11! (22.6%)!patients!were! in! remission,!as!determined!by!CSSfree!
PGA!of! no!disease! activity,! as! compared! to! 15! (29.4%)! at! 6!months,! and! 26! (51.0%)!
patients!at!12!months!(p<0.001,!ChiSsquared!analysis).!!PGA,!CRP!and!PCDAI!improved!
at! each! time! point! (Figure! 5.3).! ! However,! even! though! ESR! did! show! a! significant!
decrease!from!baseline!to!12!months,!this!was!small! (median![IQR]!at!0!months!23.0!
[8.0!S!34.0]!vs!14.0![8.0!S!31.0]!at!12!months;!p<0.0001).! !PGA!was!available!for!each!
patient! at! every! time! point.! CRP,! ESR! and! PCDAI!were! analysed! using! the! Friedman!


































































































































































































































































































































































































































































































































































































Within! this! cohort,! the!MCV!also! increased! significantly! over! the!12!months,! from!a!
















































CS!use!decreased!over! the!12!months,! from!52.9%![27]!of!patients!at! the!start!of! thiopurine!
therapy,! to! 51.0%! at! 3! months,! 31.4%! at! 6! months! and! 13.7%! at! 12! months! (Chi! squared!
analysis!p<0.0001)!
!
Approximately! half! of! the! patients! (25/51! patients;! 49%)! started! on! AZA! had! either!
bowel!resection!or!antiETNF!therapy! in!addition!to!AZA!over!the!1!year!study!period.!!
This,! of! course,!makes! it! very! difficult! to! properly! assess! the! response! to! thiopurine!

































































































































































































































































































































































































































































































































































































































The! mean! [SD]! height! SDS! at! the! initiation! of! thiopurine! therapy! was! :0.35! [1.20]!
(Figure! 5.7)! There! was! no! association! seen! between! ESR! and! height! SDS! (p=0.17,!
multivariate!analysis).!!Surprisingly,!multivariate!analysis!found!no!association!between!
PCDAI!score!and!height!SDS!(p=0.34).!!However,!there!was!a!trend!towards!CRP!being!









Despite! the! improvements! seen! in!markers!of!disease!activity!over! the!year,!overall,!
there!was!no!improvement!seen!in!height!SDS!scores.!!In!fact,!height!SDS!significantly!
decreased!during!this!time!from!a!median![IQR]!of!:0.26![:1.19!to!+0.38]!at!0!months,!:





thiopurine! therapy! at! 12!months,! as! compared! to! the! non:responders,! a! significant!
difference!was!seen!in!change!of!height!SDS!over!the!12!months!between!the!groups.!!
The! responders! had! a!median! [IQR]! change! in! height! SDS! of! 0.08! [:0.06! –! 0.19],! as!










There! was! no! improvement! in! height! SDS! seen! over! the! course! of! 12! months! following!





12!months! (p<0.001).! C)! Responders! to! thiopurines! had! better! growth! over! the! 12!months!












































Our! definition! of! response! was! CS:free! PGA! of! inactive! disease.! ! Therefore,! it! is!
possible!that!the!differences!in!height!SDS!between!responders!and!non:responders!to!
thiopurines!might!be!a!reflection!of!CS!use.!!Overall,!58.8%!(30/51)!of!patients!received!
a! course!of! CS! at! one! time!during! the! study!period.! !However,! although! the!non:CS!












Figure' 5.9' Change' in' height' SDS' in' children' treated' with' azathioprine' who' received'
corticosteroids'compared'with'those'who'did'not'
Although! the!non:CS!group!had!a!higher!median! [IQR]!change! in!height!SDS! (+0.03! [:0.19! to!















































! RBCs! [270].! ! Therefore! within! the! 26! responders! to! azathioprine,! we!











































Mutlivariate! analysis! did! not! show! any! statistically! significant! association! between!
change! in!height!SDS!and!gender! (0.58),!ethnicity! (0.24),!disease! location!(p=0.43)!or!
disease! behaviour! phenotype! (according! to!Montreal! classification)! (p=0.82),! age! at!
starting! AZA! (p=0.60)! or! disease! duration! at! the! time! of! starting! AZA! (p=0.41).!!
However,! there!was!a!statistically!significant!association!with!TPMT!(p=0.04).! !Higher!
TPMT! levels!were!associated!with! smaller! changes! in!height! SDS.! ! It! is!possible! that,!
because! of! the! increased! enzyme! activity,! the! circulating! concentrations! of! active!
thiopurine! metabolites! were! lower.! ! However,! as! 6:TGN! levels! were! not! routinely!
measured!in!this!cohort!of!patients,!we!cannot!test!this!hypothesis!in!this!study.!
50%! (25/51)! of! patients! had! either! surgery! or! anti:TNF! therapy! in! addition! to! AZA!
during!the!year.!!However,!there!was!no!significant!difference!in!change!in!height!SDS!




















Figure' 5.11' Change' in' height' SDS' in' patients' who' remained' on' azathioprine' alone' as'
compared'to'those'who'underwent'surgical'resection'or'infliximab'treatment'
There!was! no! significant! difference! in! change! in! height! SDS! over! the! year! between!patients!
that!remained!on!AZA!alone,!and!those!who!also!received!surgery!or!anti:TNF!therapy!with!the!






also! receive! thiopurines.! ! Therefore,! it! is! not! possible! to! separate! the! effects! of! the!
thiopurine! from! the! anti:TNF! effects! in! the! group! receiving! an! anti:TNF.! ! However,!
when!comparing!changes! in!height!SDS!between!patients!who!were! started!on!anti:
TNF! therapy!and! those!who!were!not,!no!statistically! significant!difference!was!seen!
(p=0.71)!(Figure!5.12.A).!!!





















We! further! examined! the! 20! patients! who! were! commenced! on! anti:TNF! therapy.!!
These! patients! were! also! followed! up! for! a! 12:month! period! following! initiation! of!
therapy.!Due!to!the!small!number!of!patients,!in!order!to!try!and!avoid!type!I!or!type!II!
errors,! data! was! only! collected! at! 0! and! 12! months.! ! 50%! (10/20)! patients! had!
moderate:severe!disease!at!diagnosis,!as!classed!by!PGA.!!This!significantly!decreased!
to!15%!(3/20)!after!12!months!of!treatment!(p=0.04,!Fisher’s!exact!test).!8/20!(40%)!of!
patients!had!a! complete! response! to!anti:TNF! therapy!at!12!months,!as!defined!bby!
CS:free! PGA! of! inactive! disease.! ! However,! there! was! no! improvement! seen! in! ESR!

























































































































Thiopurines! were! well! tolerated! in! our! cohort! of! patients,! with! 12%! of! patients!




Thiopurines! were! efficacious! in! our! cohort! of! patients.! ! Overall,! markers! of! disease!




seen! in! the!Markowitz! randomised! controlled! trial! (2000)! [209],! CS!usage!decreased!
over!the!year..!!!
A!major! difficulty! in! interpreting! these! results! comes! from! the! fact! that! 50%!of! this!




surgical! relapse! [295].! ! Therefore,! it! is! difficult! to! determine! the! effect! of! the!






months.! !Of!course,! it! is! likely!that!several!patients!would!have!been!started!on!anti:
TNF! therapy! or! have! had! surgical! resection! due! to! the! presence! of! active! disease!
despite! AZA,! and! therefore! removing! them! from! analysis! does! not! leave! a!
representative! group.! ! Nevertheless,! overall,! our! results! suggest! that! thiopurines! do!
reduce!disease!activity!in!children!with!active!CD.!!!!
No!previous!studies!have!demonstrated!any! improvement! in!growth! in!children!with!
CD!as!a!result!of!thiopurine!therapy![191,!209,!219].!!However,!these!studies!have!all!
been!performed! in!centres! that!use!CS!as!primary! induction!therapy! for! remission! in!
children! with! CD.! ! At! our! centre,! we! use! EEN,! which! has! well! documented! anti:
inflammatory! [136,! 188]! as! well! as! growth! promoting! [164]! effects.! ! Therefore,! we!
hypothesised! that! in!our!cohort!of!patients,! improved!growth!would!occur!alongside!
improvements! in! disease! activity.! Although! overall! our! patients! showed! a! slight!
decrease!in!height!SDS!over!the!12!months,!which!occurred!regardless!of!whether!CS!
were! used! or! not,! patients! who! were! classed! as! responders! to! thiopurines! at! 12!
months!showed!better!growth!than!the!non:responders!(Figure!5.8.C).!!This!is!the!first!
study!that!has!demonstrated!an!improvement!in!growth!related!to!thiopurine!therapy!
at! recommended!doses.!However,! these! results!need! to!be! interpreted!with! caution!
due!to!the!high!numbers!of!patients!who!escalated!to!anti:TNF!therapy!in!our!cohort,!











children! with! CD.! ! In! our! patients,! we! did! not! find! any! improvement! in! height! SDS!
following!12!months!of!treatment!with!anti:TNF!therapy.!!This!data!agrees!with!results!
described!by!Pfeffercon!et#al! (2009),who!found!no!sustained!benefit! from!this!either!
[220].! ! However,! our! numbers! were! very! small,! with! only! 13! patients! treated! with!
infliximab! having! growth! data! available! at! 1! and! 12! months.! ! Indeed,! Pfeffercorn's!






This! study! has! re:evaluated! the! effectiveness! of! thiopurines! in! children! with! CD! in!
everyday! clinical! use.! ! There! was! a! diverse! population! of! patients! included! in! this!
study,! with! varying! disease! location,! activity! and! duration,! amongst! other! factors.!!
Therefore,! this! study!was!able! to!demonstrate! thiopurine!efficacy!on!disease!activity!







cohort! of! patients!was! 1.56! years.! ! This! suggests! that! thiopurines! are! still! of! clinical!




completely! dependent! upon! hospital! records! and! clinical! notes! for! data! collection,!
which! were! in! some! cases! incomplete.! ! There! was! no! standardised! management!





was! routinely! available.! ! This! allows! clinicians! to! determine! whether! lack! of! or!





would!be!been!very! interesting! to! see!how!clinical! and! laboratory! indices!of!disease!
and!changes!in!height!SDS!correlated!with!6:TGN!levels.!!Although!MCV!changes!have!
been!reported!as!being!correlated!to!TGN! levels! [270]!and!clinical! response,! this!has!
been! found! to! be! a! less! useful! guidance! regarding! clinical! decisions! than! TGN! levels!









this! study! with! this! tool! available.! ! Of! particular! interest! would! be! to! look! for! any!
correlation!between! change! in! height! SDS! and!6:TGN! levels,! especially! given!how! in!
our! cohort! of! patients,! higher! TPMT! levels!were! significantly! associated!with! poorer!
linear! growth.! ! If! it! was! found! that! height! SDS! were! higher! in! patients! in! whom!
therapeutic! levels!of!6:TGN!were!achieved,! then!this!provides! important! information!
regarding!the!management!of!children!with!CD!who!have!poor!growth.!
As! mentioned! above,! the! mean! time! from! diagnosis! to! starting! AZA! therapy! was!
approximately!a! year.! ! It! is!possible! that! if!AZA!was! started!alongside!EEN! to! induce!
remission!in!CD,!then!further!beneficial!effects!on!linear!growth!will!be!seen.!Mucosal!
healing! is!associated!with!prolonged!remission! in!patients!with!CD![215,!299],!and! in!
children,! improved! growth! [296].! ! As! does! IFX,! EEN! is! known! to! promote! mucosal!
healing! [174,! 188],! but! without! the! adverse! effects! associated! with! anti:TNFs! [300:













PCDAI,! CRP,! and! to! a! lesser! extent! ESR,! all! showed! improvement! after! initiation! of!
therapy.!!Although!responders!to!thiopurines!at!12!months!showed!better!growth!than!
non:responders,! overall! height! SDS! significantly! decreased! over! the! 12!month! study!
period.!Treatment!with!biologics!conferred! !no! improvement! in!height!SDS!over!a!12!




















Inflammation!per# se! has! direct! effects! upon! growth! in! children!with! CD! and! growth!
failure,!which!occurs!separate!from!its!effects!on!appetite!and!nutritional!intake![123].!!
Therefore,! treatments! that! resolve! the! inflammation,! such! as! EEN! [164]! or! anti:TNF!
therapy! [293],! result! in! improved! growth.! ! Therefore! the! optimum! treatment! for!
improving! growth! is! the! same! as! the! treatment! for! CD! in! general:! to! eliminate! the!
inflammation.!!However,!there!are!some!patients!whose!disease!remain!intractable!to!
treatment!despite!our!best!efforts,!and!so!therefore!continue!to!grow!poorly!despite!
fully!optimising! treatment! [220].! !There! is!currently!no!agreed!treatment! to! improve!
growth! in!these!patients.! !Studies!performed!on!children!with!constitutional!delay! in!
growth!and!puberty!have! found! that! these! children!are!at! increased! risk!of!bullying,!
poor!self:esteem!and!depression!than!those!who!grow!normally![305:307].!!Although!
no!such!studies!have!been!performed!in!children!with!CD,!it!is!likely!that!poor!growth!










CD! and! growth! retardation! seem! to! have! a! functional! GH! insensitivity.! ! They! have!
normal!GH!levels![137]![138]!alongside!low!IGF:1!levels![133].!!This!occurs!concurrently!
with! elevated! pro:inflammatory! cytokines.! ! The! link! between! pro:inflammatory!
cytokines,! IGF:1! and! poor! growth! has! been! demonstrated! in! CD! and! also! in! other!







a! recognised! therapy! to! improve! growth! in! children!with! GH! insensitivity! syndrome!
(GHIS)!due!to!genetic!defects!of!the!GH!receptor!or!IGF:1!gene![236,!237].!!However,!
restoring!IGF:1!levels!in!children!with!CD!is!not!so!straightforward.!!There!are!multiple!
differences! between! children!with! CD! and! those!with!GHIS.! ! Children!with!GHIS! are!
significantly!younger!at!the!time!of!receiving!treatment.!!The!compartments!of!the!IGF:
1!system,!including!the!IGF!binding!proteins,!cannot!be!assumed!to!distribute!as!they!
do! in! younger! children.! ! Also,! GHIS! is! not! associated! with! the! presence! of!
inflammation.! ! As! has! been! discussed,! pro:inflammatory! cytokines! have! deleterious!
effects!on! the!GH/IGF:1!axis.! !Therefore,! this!may!also!alter! the!pharmacokinetics!of!
rhIGF:1.! ! In! addition,! CD! is! often! associated! with! the! presence! of! protein:losing!







of! IGF:1.! ! In!addition,!high! levels!of! IGF:1!may!be!harmful.! !Patients!with!acromegaly!
who!have!very!high!concentrations!of!GH!and!IGF:1,!maintained!over!several!decades,!
have! double! the! incidence! of! colon! cancer.! ! Studies! have! shown! that! the! increased!
cancer!risk!was!seen!in!individuals!whose!circulating!IGF:1!was!≥!+2.5!SDS![238].!!This!
needs! to! be! considered! in! children!with! CD! as! inflammation! is! also! a! risk! factor! for!
intestinal!cancer.!!!
Therefore,! for!rhIGF:1!to!be!therapeutically!useful,! its!circulating! levels!over!the! long!
term!should!be!returned!to!normal!values!by!replacement,!but!not!given!in!excess.!!A!
mathematical! model! for! administration! of! rhIGF:1,! based! on! detailed!
pharmacokinetics! (PK)! would! help! resolve! these! issues.! ! This! would! enable! us! to!













Eight! children! with! active! CD! and! height! velocity! <:2! SDS! for! age! and! gender! were!
recruited!into!the!study.!!The!median!(range)!age!was!12.97!(10.67!:!14.82)!years.!!At!






used! in! the!mathematical!model,! and! so! these! differences! did! not! affect! the!model!














LN01! LN02! LN03! LN04! LN05! LN06! LN07! LN08!
Baseline!characteristics!
Gender! F! F! M! M! F! F! M! M!
Age! 13.11! 11.5! 14.23! 10.67! 14.82! 12.7! 12.82! 14.66!































3.34! 0.82! 0.88! 0.49! 2.63! 2.28! 0.08! 0.45!
HV!SDS!at!
recruitment!




L1! L2! L3! L3! L1! L3! L1! L1!
Behaviour! B1! B1! B3! B3! B2! B1! B2! B1!
Upper! N! N! Y! N! Y! Y! N! N!




HV!SDS!! :2.11! :2.14! :1.84! 0.36! 1.69! 3.55! :4.43! :4.88!
PCDAI! 12.5! 20! 17.5! 10! 47.5! 15! 12.5! 10!
CRP!mg/l! 36! <5! 26! <5! 82! 12! 10! <5!




HV!SDS! :1.42! :3.91! 1.55! :4.04! 5.97! 2.33! :1.04! 0.82!
PCDAI! 15! 20! 17.5! 5! 7.5! 35! 0! 0!
CRP!mg/l! 69! 5! 22! <5! <5! 12! <5! <5!













Baseline! IGF:1! levels!were!measured! in! each! patient! at! each! admission.! ! They!were!
then!converted!to!SDS!according!to!the!patient's!age!and!gender!(Appendix!5).!
7! of! the! 8! patients! had!baseline! IGF:1! SDS! <0! at! their! first! admission! (Figure! 6.1.A),!
with!a!median![range]!SDS!of!:2.02![:3.19!:!1.05].!!All!8!patients!had!baseline!IGF:1!SDS!


















































Spearman's! rank! correlation! showed! no! statistically! significant! correlation! with!
baseline!IGF:1!SDS!and!either!HV!SDS!(r=0.11,!p=0.59)!(Figure!6.2.A)!or!PCDAI!(r=:0.01,!
p=0.99)! (Figure! 6.2.B).! ! There! was! no! statistically! significant! correlation! between!


















































































































































































































IGFBP*3! is! the!main! carrier! of! IGF*1! in! the! circulation.! !We!measured! levels! in! each!
patient.! ! These! values! were! also! converted! to! SDS! according! to! each! patient's! age!
(Appendix!5).!!Interestingly,!we!found!that!IGFBP*3!SDS!were!low!in!all!patients,!with!a!
median![range]!value!of!*1.71![*2.70!to!*1.08]!(Figure!6.3.A).!!!PLE!is!commonly!present!









































































































































All!of! the!participants!completed!both!parts!of! the!study.! !The!rhIGF*1!was!generally!
well!tolerated.!!The!most!common!side!effect!experienced!by!patients!with!GHIS!was!
hypoglycaemia! [236].! There! were! no! episodes! of! hypoglycaemia! in! any! patient!
following! a! single! dose! of! rhIGF*1! (Figure! 6.4.A).! ! However,! during! the! second!
admission,! one! patient! (LN01)! had! a! single! asymptomatic! hypoglycaemic! episode!
(blood! glucose! <3.5!mmol/l)! following! the! second! dose! of! rhIGF*1! at! 12! hrs! (Figure!
6.4.B),!having!not!eaten!before!the!dose!was!administered.! !This!was!corrected!with!











































A)! No! episodes! of!
hypoglycaemia! in! any! of!
the! patients! following! a!
single!sc!dose!of!rhIGF*1.!!





dose! or! rhIGF*1! at! 12!
hours.! ! This! was!
corrected! with! oral!
glucose.! ! C)! There! were!




























































































Despite! the! variability! in! disease! activity! and! location! between! patients,! a! single! sc!
injection! of! rhIGF*1! at! a! dose! of! 120! µg/kg! significantly! increased! circulating! IGF*1!
levels,!with!peak!concentrations!being! reached!between!3*4!h!after! injection! (Figure!
6.6).!!Plasma!IGF*1!SDS!were!increased!from!a!median!(range)!of!*2.02!(*3.19!to!+1.05)!
to!1.81!(*1.01!to!+7.67)!at!the!first!admission!(p=0.008,!Wilcoxon!signed!rank)!(Figure!
6.6.A),! and! *2.42! (*3.20! to! *0.91)! to! +1.17! (*0.04! to! 2.89)! (p=0.008,!Wilcoxon! signed!




presence! of! PLE! would! blunt! the! ability! of! sc! rhIGF*1! to! achieve! significant! peak!
concentrations.! ! However,! no! statistically! significant! correlation!was! found! between!













and! compared! this! to! the! IGF*1! SDS! according! to! their! chronological! age.! !However,!




































A)! IGF*1! SDS! below! the!





of! rhIGF*1! (P=0.008! for!
both! analysis).! ! C)!
Variations! in! PLE,! as!
measured! by! faecal! A1AT,!
did! not! correlate!
significantly! with! changes!
in! IGF*1! (r=0.17,! p=0.70).!!
D)! IGF*1! concentrations!

























































































During! the! second!admission,! the!children! received! twice*daily!doses!of! rhIGF*1!at!a!
dose! of! 120! µg/kg,! as! used! in! children! with! GHIS! (Figure! 6.8).! ! IGF*1! SDS! were!
calculated!from!the!results!of!each!sample!collected!from!every!patient!(Figure!6.8.B).!!
From! this! section! of! the! study! we! determined! the! average! IGF*1! concentration! by!





























using! the!area!under! the!curve!divided!by! time.! !This!value!was! then!converted! to!a!
SDS,!according!to!each!patient’s!age!and!gender,!thus!giving!us!an!average!IGF*1!SDS!
for! each! patient! following! BD! dosing! of! rhIGF*1! at! 120! µg/kg/dose! (Table! 6.2).! !We!
found!that!some!patients!had!appropriate!SDS,!whereas!others!had!an!average!IGF*1!
SDS!of! >+2.5;! the! level! known! to!be!associated!with! increased! colonic! cancer! risk! in!




















































































Patient! LN01! LN02! LN03! LN04! LN05! LN06! LN07! LN08!
Average!
IGF*1!SDS!







From! our! study! results,! we! developed! a! model! from! which! the! dose*concentration!
relationship!between!rhIGF*1!and!circulating!IGF*1!concentrations!could!be!derived.!!A!
turnover! model,! which! accounted! for! both! endogenous! production! and! exogenous!
dosing! of! IGF*1! (Figure! 2.3),! was! fitted! to! the! data! using! non*linear! mixed! effects!
analysis.! ! Four! fixed! effects! were! estimated:! Ksyn! (endogenous! synthesis! rate,! Ka!
(exogenous! absorption! rate! following! subcutaneous! injection),! CL! (IGF*1! clearance),!
and!VD!(volume!of!distribution).! !The!model!considered!two!levels!of!random!effects,!
which! resulted! in! improved! fit:! the! random!effects!of! inter*subject!variability!on!Ksyn!
and! CL,! and! inter*occasion! variability! on! Ksyn.! ! By! extrapolating! the! model! to!
hypothetical! patients! with! real! Crohn’s! disease! demographics! the! robustness! of! the!
model!fit!was!demonstrated.! !The!effects!of!potentially!relevant!covariates!were!also!
included! to! improve! the!model! fit.! ! These! included!ESR,!CRP,! the!degree!of!PLE!and!
PCDAI.! Only! PCDAI,!when! added! to! Ksyn,! significantly! improved! fit.! ! Increased! PCDAI!
scores! correlated! with! lower! Ksyn! (Figure! 6.9.A;! p<0.001).! ! However,! linear! growth!









chi! squared! 1! distribution! is! 0.07.!! This! means! that! whilst! both! wPCDAI! and! PCDAI!
score!significantly!improved!the!fit,!there!was!no!significant!difference!between!these!
improvements.! !Hence!using!either!PCDAI!or!wPCDAI!will! give! the! same! result.! ! This!
suggests!that!disease!severity!is!the!major!driver!of!IGF*1!synthesis!rate!both!between!
patients! and! in! the! same! patient! on! different! occasions.! ! Including! PCDAI! score!
significantly! eliminated! inter*individual! variability! in! the! model.! ! Model! predictions!
were! graphically! compared! to!observed!data!with! good!agreement!observed! (Figure!
6.9.B!&!C).! ! The! absence!of! a! trend! in! the!distribution!of! the! standardised! residuals!
meant! the!parametric!model! assumptions!were! correct! (Figure!6.9.D!&!E).! ! The! two!













(A)! Increasing!PCDAI!significantly! (p<0.001)!diminishes! the!estimates!of!Ksyn! in! the!covariate!
model! building.! (B)! Population! model! predictions! versus! observed! concentrations! are!
unbiased,! indicating!good! structural!model! fit.! (C)! Individual!model!predicted!concentrations!
are! in!agreement!with!observed!concentrations.! (D)!Conditional!weighted!residuals! (CWRES),!
(a!form!of!standardised!residuals)!expected!to!follow!the!Normal!Independent!Distribution!lay!











The! purpose! of! the!modelling! approach!was! to! be! able! to! quantify! the! relationship!
between!endogenous!IGF*1!production!and!exogenous!dosing!and!to!understand!how!
IGF*1! average! concentrations! (area! under! curve/time)! can! be! adjusted.! ! Current!
understanding! of! IGF*1! concentrations! and! thresholds! of! safety! derived! from!
acromegaly!patients.! !Although!we!do!not!understand! the!exact!pathogenesis!of! the!
increased!malignancy! risks,! it! is! thought! to! be! likely! to! decades! worth! of! sustained!
exposure! to! elevated! IGF*1! levels! >+2.5! SDS! [238].! ! Even! though!our!patients!would!
receive! a! much! shorter! duration! of! treatment,! due! to! the! risks! of! malignancy!
associated! with! chronic! intestinal! inflammation,! ! we! defined! the! optimal! IGF*1!
concentration!range!as!0! to!+2!SDS.! !We!simulated!different!dose!scaling! regimes! to!
predict!and!maximise!the!likelihood!that!an!individual!will!maintain!IGF*1!levels!within!
the! target! range.! ! 92.7%! of! children!were! predicted! to! have! IGF*1! levels!within! the!


























of! circulating! IGF*1.! Scaling! by! weight,! age! group! and! PCDAI! score! limits! average! IGF*1!














As! has! been! previously! described! [133],! the! children! in! our! cohort! who! had! active!
inflammation!and!growth!retardation!also!had!low!circulating!concentrations!of!IGF*1!
(Figure!6.1).!!The!best!strategy!to!increase!IGF*1,!and!therefore!to!improve!growth,!is!
the! resolution!of! the! inflammation! [136].! ! However,! there! are! some! children!whose!
inflammation! remains! intractable! to! treatment.! ! We! need! a! distinct! strategy! to!
accelerate!growth!in!the!group.!
RhIGF*1!has!thus!far!only!been!used!as!a!treatment!in!children!with!GHIS.!!Although!it!
has! been! shown! to! be! very! efficacious! at! increasing! IGF*1! levels! in! these! children,!
children!with!CD!present!a!different!challenge!due!multiple!reasons,!including!differing!
age! range,! the! presence! of! inflammation! and! protein*losing! enteropathy,! amongst!
other!things.!!However,!all!of!the!children!in!our!study!increased!their!circulating!IGF*1!
concentrations! in! response! to! exogenous! rhIGF*1,! with! levels! being! maintained!






As! rhIGF*1! has! only! been! used! in! children! with! GHIS,! it! is! difficult! to! decide! on! an!





able! to! increase! IGF*1! levels! to!within! the! normal! range! and! no! higher! as! sustained!
high! IGF*1! concentrations! are! associated! with! increased! risk! of! colonic! cancer! in!
middle! aged! and! older! patients! with! acromegaly! [238,! 320].! ! Normal! IGF*1!
concentrations!vary!at!different!ages!of!childhood!(Appendix!5),!and!so!rhIGF*1!dosage!
needs!to!be!altered! in! line!with!this.! ! In!addition,!determining!an!appropriate!dosing!
regimen!in!children!with!CD!is!made!all!the!more!complicated!by!the!diversity!seen!in!
patients.! ! As! demonstrated! by! the! patients! in! our! study,! disease! activity! varies!
considerably!not!only!between!patients,!but!also!within!the!same!patient!at!different!
times!(Table!6.1),!and!so!rhIGF*1!requirements!will!also!vary!due!to!this.!
In! order! to! use! our! data! to! recommend! a! dose,! we! used! a! modelling! approach! to!
kinetics! and! dosing.! ! In! this! study,! we! fitted! a! structural! model! that! simplified! the!
system!without! losing! the!biological! interpretation!of! the!parameters.! !Mixed!effects!
modelling!allowed!for!the!addition!of!inter*individual!and!inter*occasion!variability,!as!
well!as!residual!variability!(differences!between!predicted!and!observed!values).!!This!
enabled! simultaneous! model! fit! for! all! patients! and! exploration! of! covariate!
















PK! study,! from!which!we!were!able! to! form!a!mathematical!model! to!determine!an!
IGF*1!dosing!regimen!that!restores!IGF*1!concentrations!to!the!normal!range,!and!not!
in!excess.!!As!our!patients!had!two!separate!admissions,!this!allowed!for!us!to!perform!
mixed! effects! modelling! adding! inter*occasion,! as! well! as! inter*individual! variability.!!
We! were! able! to! use! this! model! to! determine! the! effect! of! covariates,! such! as!
inflammatory!markers! and! PLE.! ! From! this,!we! have! been! able! to! suggest! a! specific!
dosing!schedule!based!upon!a!child's!age,!weight!and,!importantly,!PCDAI!also.!!A!child!
with! CD!will! have! variable! amounts! of! inflammation! during! their! course! of! disease.!!
This! dosing! regimen! allows! for! this! fact.! ! This! study! has! demonstrated! how!
pharmacokinetic!mathematical!modelling!can!be!used!to!good!effect!in!a!clinical!trial.!!
We!found!that!the!dosing!regimen!used!in!children!with!growth!hormone!insensitivity!
syndrome! was! not! appropriate! for! all! children! with! CD.! ! The! formation! of! a!
mathematical!model!has!allowed!us!to!determine!an!appropriate!dosing!regimen!for!
use!in!further!studies.!
95%!of! IGF*1! circulates! bound! to!binding!proteins,!with! the! remaining! 5%!being! the!
biologically! active! free! IGF*1.! ! Our! patients! all! had! low! circulating! IGFBP*3!
concentrations,!and!therefore!rhIGF*1!may!have!increased!the!proportion!of!free!IGF*













robust! mathematical! model! was! formed! from! our! results,! which! showed! a! good!
response! to! simulation! testing.! !However,!more! patient! data!would! further! increase!
the! accuracy! of! the! mathematical! model.! ! This! is! the! advantage! of! creating! a!






active! CD! and! growth! retardation! back! to! within! the! normal! range,! and! used! a!







therapy! to! growth! in! children! with! CD! have! been! studied,! with! some! encouraging!
results![234,!235].!!It!remains!to!be!seen!as!to!which!of!rhGH!and!rhIGF*1!is!the!more!
efficacious.! ! A!multicentre! randomised! controlled! trial! comparing! rhIGF*1! and! rhGH!






IGF*1.! ! These! concentrations! can! be! restored! into! the! normal! range! by! exogenous!
injections! of! rhIGF*1,! which! is! well! tolerated.! ! There! are! concerns! about! exogenous!
administration!of!rhIGF*1!as!high!IGF*1!concentrations!may!predispose!to!colon!cancer.!!
However,! from! our! pharmacokinetic! studies! we! were! able! to! formulate! a!
mathematical!model! of! IGF*1,!which! allows!doses!based!on!weight,! age! and!disease!












Growth! retardation! has! been! a! recognised! feature! of! children! with! CD! for! over! 50!
years! [322],! and! is! reported! wherever! CD! has! been! described! [96,! 323*325].! ! The!
recognition!and!treatment!of!growth!failure!is!a!fundamental!part!of!the!management!
of! a! child! with! CD! [49,! 55,! 191].! ! Initially! thought! to! be! solely! the! result! of!
undernutrition![107,!326],!we!now!understand!that!the!aetiology!of!growth!failure!in!
paediatric! CD! is! multifactorial! in! origin.! ! Animal! studies! have! demonstrated! the!
contribution!of!inflammation!per$se,!separate!from!its!anorexigenic!effects![123],!and!
numerous!studies!have!described!the!deleterious!effect!of!pro*inflammatory!cytokines!
upon! the! GH/IGF*1! axis! [89,! 124,! 125].! ! However,! despite! these! increases! in! our!
knowledge! of! its! pathogenesis,! growth! retardation! remains! a! common! problem! for!
children!with!CD![220].! !With!the! increasing!prevalence!of!paediatric!CD![24,!34,!35],!
and! the! question! as! to!whether! the! age! of! onset! is! getting! younger! [32,! 35],! this! is!




been! described! in! previous! reports! [42,! 101],! we! found! that! the! duration! of! time!
between!the!onset!of!symptoms!and!diagnosis!correlated!negatively!with!height!SDS!at!






of! growth! retardation! in! these! patients! might! be! due! to! unchecked! disease!
suppressing!growth,!or!related!to!the!site!of!the!inflammation![53].!!As!first!described!
by!Crohn!himself![327],!!jejunal!disease!is!commonly!associated!with!poor!growth![99,!
101].! ! However,! in! our! study,! although! we! found! that! patients! with! isolated! small!
bowel!disease!were!most! likely! to!experience!a! longer!duration!of! symptoms! to! the!
time! of! diagnosis,! multivariate! analysis! showed! no! correlation! between! disease!
location! and! height! SDS.! ! Indeed,! the! only! factor! that! correlated!with! height! SDS! at!












proven! efficacy! [55].! ! Although! the! short*term! beneficial! effects! of! EEN! to! patients,!
both! in! terms! of! disease! activity! and! in! relation! to! linear! growth,! have! been! well!






following! EEN! induction! therapy! would! have! a! sustained! CS*free! clinical! remission!
when!compared!to!non*responders,!and!that!this!would!result!in!better!linear!growth.!!
However,!even!though!we!found!that!responders!to!EEN!did!show!better!linear!growth!
across! a! 5! year! follow! up! period,! this! occurred! despite! no! differences! in! time! to!






healing! with! EEN! use! [188],! and! that! this! results! in! continuous! beneficial! effects! to!
growth.!!Another!explanation!may!relate!to!differential!changes!in!intestinal!microflora!
and! subsequent! changes! in! local! inflammatory! immune! responses! and! antigenic!
potency.! ! Patients!with! CD! exhibit! altered! intestinal!microbiota! as! compared! to! the!
general!population![4,!15,!16],!and!children!who!respond!to!EEN!show!an!alteration!in!
their!microbiota! after! treatment! [329*331].! ! However,! it! is! not! known!whether! this!









from!North! America,!where! CS! are! preferentially! used! over! EEN! as! the! induction! of!
remission!agent!of!choice![170].! ! Interestingly,! in!our!unit,!where!we!use!EEN!as!first!




still! did! not! show! improved! linear! growth! in! following! thiopurine! therapy,! despite!
having!clinical!and!biochemical!improvement!of!disease!activity.!!However,!none!of!the!
patients!in!our!study!initiated!thiopurine!therapy!at!the!time!of!diagnosis.!!Therefore,!it!
is! still! possible! that! starting! thiopurine! therapy! at! the! same! instance! as! EEN! may!
support!growth.!!EEN!promotes!mucosal!healing![188],!and!as!we!report!in!this!thesis,!
response! to! EEN! in! our! patients! is! associated!with! sustained! beneficial! effects! upon!
linear! growth.! ! Adult! studies! comparing! the! efficacy! of! infliximab! as! compared! to!
azathioprine![215]!have!reported!that!patients!receiving!combined!treatment!had!the!
highest! rates! of! mucosal! healing! and! the! longest! duration! of! CS*free! remission.!!
Therefore,!it!is!possible!that!the!early!introduction!of!an!immunomodulator!alongside!
a!treatment!that!promotes!mucosal!healing!will!have!long*term!beneficial!effects!upon!
growth.! ! However,! a! randomised! controlled! trial! comparing! outcomes! in! children!
treated!at!diagnosis!with!EEN!alone!to! those! treated!with!a!combination!of!EEN!and!
thiopurine!is!needed!in!order!to!answer!this!question.!!In!addition,!although!we!did!not!





Nevertheless,! until! we! can! find! a! cure! for! CD,! there! will! always! be! children! whose!








to!establish! if! it! is!possible!to!restore!plasma! levels!to!normal! levels! in!this!cohort!of!
children.!!In!this!thesis,!we!have!demonstrated!that!it!is!possible!to!increase!circulating!
IGF*1! concentrations! in! children!with!CD! following!exogenous!dosing.! !We!have!also!
demonstrated! a! way! in! which! it! is! possible! to! restore! IGF*1! levels! into! the! normal!
range! without! entering! the! high! ranges! that! are! associated! with! increased! colonic!
cancer! risk! in! patients! with! acromegaly! [238].! ! In! order! to! do! this,! we! utilised! a!
mathematical! modelling! approach! to! kinetics! to! decide! on! an! appropriate! dosing!
regimen.!!This!has!also!demonstrated!how!PK!modelling!can!be!used!in!paediatrics!to!
beneficial! effects,! by! individualising! dosing! strategies! and! reducing! the! need! for!









In! conclusion,! despite! increases! in! our! knowledge!of! the!pathogenesis! of! CD*related!
growth! failure,! and! increased! treatment! options! available! to! us! to! help! control!
inflammation,! a! significant! percentage! of! children!with! CD! remain! growth! retarded.!!
Isolated! growth! retardation! is! associated! with! low! self*esteem! and! reduced! QOL! in!
otherwise!healthy! children! [305*307],! and!provides!an!extra!burden! to! children!with!
CD,!whose!lives!are!already!affected!by!chronic!disease.!!The!inclusion!of!assessments!
of! growth! in!both! the!PCDAI! score! [56]!and! the!Paris! classification! [55]!highlights! its!
recognition!by!treating!clinicians.!!Crucially,!its!inclusion!in!patient!forums!shows!us!its!
importance!to!our!patients!and!their!families![332,!333].!!Therefore!it!is!important!that!

























have! found!that! it! is!possible! to!restore! these! levels! into! the!normal! range! following!
exogenous!dosing!of!rhIGF*1,!and!have!utilised!a!mathematical!model!to!determine!a!
dosing!regimen!that!keeps!IGF*1!concentrations!to!within!the!normal!range,!but!not!in!
excess.! ! This! both! provides! a! dosage! of! rhIGF*1! to! be! used! in! future! trials,! and! also!
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Puberty starting before 9 years is precocious Puberty starting before 9 years is precocious
Puberty is delayed if no signs are present by 14 years
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Puberty is delayed if no signs are present by 14 years













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Puberty starting before 8 years is precocious Puberty starting before 8 years is precocious
Puberty is delayed if no signs are present by 13 years

































































































































































































































































































































   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 
















   
 
 




   
 
 




   
 
 




   
 
 






   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 




   
 
 









   
 
 




   
 
 




   
 
 




   
 
 











   
 
 




   
 
 




   
 
 
   
 
Puberty is delayed if no signs are present by 13 years








































































































































































































































































































































































































































































































































































































































































Age'!!!!!!years!!!!!!!!!!!!!!!!!Sex:!Male!!!Female! ! ! ! ! !
! ! ! ! ! ! ! ! ! Score!!!!!!!!
Subtotal!
Abdominal!pain! no!abdominal!pain! 0! !
Mild;!!no!interference!with!activities!of!daily!living(ADL)! 5!
Moderate,severe;daily!nocturnal,!interferes!with!ADL! 10!
Stools/day! 0'1!liquid!no!blood! 0! !
≤!2!semi!formed!+!small!blood!or!2'5!liquid! 5!
≥!liquid!stools,!gross!blood!,!or!nocturnal!diarrhoea! 10!













Height!velocity++!! ≤!'1!standard!deviation!from!normal! 0! !
'1!to!<!'2!standard!deviation!from!normal! 5!
≥!'2!standard!deviation!from!normal! 10!
Abdomen! No!tenderness!or!mass! 0! !
Tenderness!or!mass!without!tenderness! 5!
Tenderness,!involuntary!guarding,!definite!mass! 10!
Peri'rectal!disease! None,!asymptomatic!tags! 0! !
1'2!indolent!fistula,!scant!drainage,!non'tender! 5!
Active!fistula,!drainage,!tenderness,!or!abscess! 10!



















ESR!(mm/hr)! <!20! 0! !
20'50! 2.5!
>50! 5!






























































































































































































































































































































































































































































































































































































& & & & & & &
1'2! 30'122! 76! 23! 56'144! 100! 22!
3'4! 54'178! 116! 31! 74'202! 138! 32!
5'6! 60'228! 144! 42! 82'262! 172! 45!
7'8! 113'261! 187! 37! 112'276! 194! 41!
9'10! 123'275! 199! 38! 140'308! 224! 42!
11'12! 139'395! 267! 64! 132'376! 254! 61!
13'14! 152'540! 346! 97! 192'640! 416! 112!
15'16! 257'601! 429! 86! 217'589! 403! 93!
17'18! 236'524! 380! 72! 176'452! 314! 69!
19'20! 281'510! 371! 76! 217'475! 323! 75!
21'30! 155'432! 289! 73! 87'368! 237! 74!
31'40! 132'333! 226! 62! 106'368! 225! 71!
41'50! 121'237! 160! 42! 118'298! 205! 60!
51'60! 68'245! 153! 48! 53'287! 172! 55!
61'70! 60'220! 132! 34! 75'263! 180! 51!





















Age& Range&(mg/l)& Mean& SD&
! ! ! !
0'2m! 0.2!'!5.1! 2.1! 1.7!
3'6m! 0.7!'!5.6! 3.4! 1.3!
7'11m! 0.7!'!7.9! 4.0! 2.3!
12m'2y! 0.9!'!9.3! 5.5! 2.5!
3'4y! 1.9!'!10! 6.8! 2.7!
5'7y! 2.3!'!11! 7.2! 2.5!
8'10y! 4.2!'!13! 8.9! 2.5!
11'13y! 5.6!'16! 12! 3.6!
14'18y! 5.6!'!16! 12! 4.2!
19'25y! 7.0!'!16! 12! 2.5!
26'35y! 7.0!'!16! 12! 2.1!
36'45y! 7.0!'!16! 11! 1.7!
46'55y! 7.0!'!16! 11! 2.1!

























































































































































Will my child’s taking part in this study be kept confidential? 
 
Only the doctors and members of the hospital who look after you will be able to identify the medical 
information we collect as being from your child. The results of the tests we carry out will be shared by 
other researchers, but no-one will know that the measurements have come from you. The research we do 
can be inspected by inspectors appointed to safeguard patients’ interests. We would like to ask you if they 
can look at your child’s records if they wish. 
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are!not!happy!with! any!proposed! compensation! you!may!have! to!pursue! your! claim! through! legal!
action.!
!





































































































































































Will my taking part in this study be kept confidential? 
 
Only the doctors and members of the hospital who look after you will be able to identify 
the medical information we collect as being from you. The results of the tests we carry 
out will be shared by other researchers, but no-one will know that the measurements 
have come from you. The research we do can be inspected by inspectors appointed to 
safeguard patients’ interests. We would like to ask you if they can look at your records 
if they wish. 
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! Queen!Mary! University! of! London! has! agreed! that! if! you! are! harmed! as! a! result! of! your!












telephone! 020! 7377! 6335,! minicom! 020! 7943! 1350,! or! email!
pals@bartsandthelondon.nhs.uk,! you! can! also! visit! PALS! by! asking! at! any! hospital!
reception.$
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